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OP 1.0

HIV persistence: to the periphery and beyond

J.V. Garcia Martinez

Division of Infectious Diseases/UNC CFAR, University of North Carolina at Chapel Hill, USA

Despite suppressive antiretroviral therapy (ART), HIV reservoirs persist in most patients. The latent reservoir consists of cells harboring transcriptionally silent provirus and the residual active reservoir is characterized by low level viral RNA production. The goal of eradication therapies is to eliminate these viral reservoirs from the body. However, our knowledge of the systemic nature of HIV reservoirs is incomplete. To provide a comprehensive characterization of the anatomical distribution of persistent HIV, we performed a systemic examination of the latent and residual active HIV reservoirs in bone marrow-liver-thymus (BLT) humanized mice undergoing ART. Our results demonstrate that the latent HIV reservoir is broadly disseminated during ART. Furthermore, each of the tissues examined exhibited low level vRNA production indicating that the residual active HIV reservoir is also systemic in nature. Our data demonstrate that HIV reservoirs are broadly disseminated *in vivo* and provide a quantitative framework for the *in vivo* efficacy evaluation of HIV eradication interventions designed to deplete HIV reservoirs.
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OP 1.1

Clones of SIV-infected cells are present in spleen and lymph nodes in rhesus macaques

S.H. Hughes^1^, A.L. Ferris^1^, G.Q. Del Prete^2^, B.F. Keele^2^, X. Wu^3^, J.D. Lifson^2^

^1^HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD, USA, ^2^AIDS and Cancer Virus Program, Leidos Biomedical Research, USA, ^3^Laboratory of Molecular Technology, Leidos Biomedical Research, USA

**Background:** We and others showed that HIV infected cells can clonally expand in patients, and that integrated viral DNA can cause the growth and persistence of infected cells. More recently, we showed that a clonally expanded cell carries an intact provirus and produces infectious HIV in a patient. Because there are limits on the samples that can be obtained from patients, we developed a model using SIV-infected rhesus macaques.

**Methods:** The methods of Maldarelli *et al.* (*Science* 2014; **345**: 179) were used to generate an integration site library from rhesus macaque PBMCs infected in culture with SIV. Six additional libraries were generated from two rhesus macaques (two lymph node and one spleen sample from each animal) that were infected with SIV for 4 weeks and then treated for 1 year with a fully suppressive cART regimen. Samples were taken during necropsy at the end of the treatment period.

**Results:** The distribution of the SIV integration sites in the large integration site library (\~50,000 independent sites) prepared from rhesus macaque PBMC infected *in vitro* was quite similar to the distribution of HIV integration sites in human PBMCs. We obtained approximately 380 independent integration sites from the monkey tissue sample and identified 13 clones of expanded cells. Cells from two of the clones were present in both the spleen and lymph node.

**Conclusions:** Cells that are infected early gave rise to expanded clones in two macaques that were treated after 4 weeks of SIV infection; at least some clones were not tissue restricted. We looked for integration sites in genes in which the integration of an HIV provirus can provide the infected cells with a selective growth advantage; there was no evidence for the selection of cells that have integration sites in either BACH2 or MKL2. Our results establish an SIV/macaque model that can be used to study the clonal expansion of infected cells using samples that cannot be obtained from patients.
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OP 1.2

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice

M.D. Marsden^1^, X. Wu^1^, B.A. Loy^2^, B.A. DeChristopher^2^, A.J. Schrier^2^, C.M.R. Kitchen^1^, E. Beans^2^, D. Fournogerakis^2^, C. Gauntlett^2^, L. Heumann^2^, R. Kramer^2^, D. Murray^3^, T.W. Chun^3^, P.A. Wender^2^, J.A. Zack^1^

^1^UCLA, Los Angeles, CA, USA, ^2^Stanford University, Stanford, CA, USA, ^3^National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

**Background:** Latently infected CD4+ T cells represent a key barrier preventing the cure of HIV. Latently infected CD4+ T cells represent a key barrier preventing the cure of HIV infection in patients treated with antiretroviral therapy (ART). One potential approach for eliminating this latent reservoir is to induce the virus to express proteins, which would make the host cell susceptible to viral cytopathic effects, immune effector mechanisms, and other therapeutic approaches targeting viral proteins. For this strategy to be successful, safe and effective methods for activating latent HIV expression are needed. We have designed and synthesized new, potent HIV latency-reversing compounds based on prostratin and bryostatin that function through protein kinase C (PKC). In the current study we aimed to test these *in vivo* using the humanized bone marrow-liver-thymus (BLT) mouse model of HIV latency.

**Methods:** Synthetic analogs of the natural PKC-activating compounds were designed and synthesized. Several of these were highly effective in reversing HIV from latency in cell line models and latently infected cells obtained *ex vivo* from ART-treated patients. Promising compounds were then evaluated for acute toxicity and bioactivity in immunocompetent mice. Based on these studies, one particularly potent and well-tolerated bryostatin analog was tested for its ability to reverse HIV from latency in HIV-infected humanized BLT mice treated with ART.

**Results:** Several tested prostratin and bryostatin analogs were more bioactive and less toxic in immunocompetent mice than the corresponding natural products. The bryostatin analog PKC modulator tested in ART-treated BLT mice was found to be capable of activating expression of latent HIV in peripheral blood and tissues following *in vivo* administration.

**Conclusions:** Designed, synthetically accessible PKC modulators are capable of inducing HIV from latency *in vitro* and *in vivo*, and might therefore be useful in efforts to eliminate reservoirs of virus that persist during ART.
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OP 1.3

Shining the RNA-Seq microscope on models of HIV latency

C.H. Woelk^4^\*\*, C.H. White^1,2^\*, A. Bosque^3^\*, B. Moesker^4^, C.A. Spina^1,5^, D.D. Richman^1,2,5^, N. Beliakova-Bethell^1,5^, V. Planelles^3^\*\*

*^1^VA San Diego Healthcare System, San Diego, CA, USA, ^2^Department of Pathology, University of California San Diego, La Jolla, CA, USA, ^3^School of Medicine, University of Utah, Salt Lake City, UT, USA, ^4^Faculty of Medicine, University of Southampton, UK, ^5^Department of Medicine, University of California San Diego, La Jolla, CA, USA*\*First authors contributed equally to this abstract. \*\*Senior authors contributed equally to this abstract.

**Background:** The paucity of latently infected cells in patients necessitates *in vitro* models for the study of HIV persistence. Transcriptomics can be used to assess model validity and to identify biomarkers of latency. Our primary objective was to use RNA-Seq to validate the central memory CD4 T cell (TCM) model of HIV latency that utilizes replication competent virus.

**Methods:** Naive CD4 T cells were isolated from the blood of four healthy donors and activated with αCD3/αCD28 beads in the presence of cytokines to induce differentiation into TCM. Cells were infected (or mock-infected) with HIV NL43 for 6 days and then cultured for 4 days in the presence of ART to induce a latent state. Both infected and uninfected conditions for each donor were subjected to reactivation. These four conditions (uninfected, UI; latently infected, LI; uninfected activated, UIA; and latently infected activated, LIA) from four donors resulted in 16 samples for RNA-Seq analysis using the Illumina HiSeq 2000 platform.

**Results:** To validate the TCM model, the LI and LIA conditions were compared to reveal the upregulation of well-known markers of activation (e.g. IL2), as well as a 7-fold increase in HIV transcription, with a shift from unspliced to multiply spliced transcripts. Therefore, this model was reflective of a latent state of HIV infection. The UI and LI conditions were then compared to identify 827 differentially expressed biomarkers of latency associated with processes such as p53 signaling and DNA damage. Comparison to microarray data published by the F. Romerio laboratory for their HIV latency model identified an overlap of 51 upregulated and 32 downregulated genes.

**Conclusions:** RNA-Seq analysis provides a powerful tool to validate models of HIV latency and screen for biomarkers. Future work will evaluate the ability of biomarkers to identify latently infected cells from HIV infected patients.
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OP 1.4

*In vivo* suppression of SIV-mediated immune activation by a p38 MAPK inhibitor combined with ART

A. Aldovini^1^\*, O. Chaudhary^1^\*, V. Narayan^1^\*, R. Veazey^2^

^1^Boston Children's Hospital, Department of Medicine and Harvard Medical School, Department of Pediatrics, Boston, MA, USA, ^2^Tulane Primate Research Center, Tulane University, Covington, LA, USA

**Background:** Differences in immune activation have been identified as the single most significant difference between AIDS-susceptible and resistant species. p308 MAPK, reported t3o be activated in HIV and SIV infection, is key to induction of interferon-stimulated genes (ISG) and is associated *in vivo* with some of the pathology produced by HIV and SIV infection. As small molecule p38 MAPK inhibitors are available and are currently being tested in human trials for other inflammatory diseases, we evaluated the effects of treating SIV-infected macaques with a p38 inhibitor in conjunction with ART.

**Methods:** Rhesus macaques were infected with SIVmac251 and cART and p38 MAPK inhibitor treatment was initiated in one group of animals 6 weeks after infection. Additional groups included ART alone, p38 inhibitor alone, and naive controls. We evaluated differences in expression of surface and intracellular molecules linked to immune activation, intracellular inflammatory cytokine expression in cell subpopulations of blood, lymph node and intestinal tissue, plasma levels of inflammatory cytokines viral loads, preservation of central memory CD4+ T cells, anti-SIV immune responses, protein levels of selected ISG.

**Results:** ART reduced viremia to levels of 70--80 copies/mL. The p38 inhibitor did not further reduce the residual viremia in blood, did not negatively affect anti-SIV immune responses and had no side effects. By itself it had no significant effect on immune activation. When combined with ART, numerous markers of immune activation were significantly reduced compared to the ART alone group. CD38/HLA-DR an Ki67 percentages in blood, lymph node and rectal CD4+ and CD8+ T cells and percentages of IL-6, IL-8, IFN-γ and IFN-α producing cells were all significantly reduced. IRF7, pSTAT1 and IP-10 protein accumulation was also reduced in APC. Significant preservation of CD4+/IL22+ and CD4+/IL-17+ T-cells in PBMC, rectal and lymph node mononuclear cells and of central memory CD4+ T cells in blood was also observed.

**Conclusions:** we conclude that the p38 MAPK inhibitor used in this studies, which is already in clinical trials for other inflammatory diseases, significantly reduced immune activation during ART treatment and could be a desirable addition to antiretroviral therapy.
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OP 1.5

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents

D.A. Kulpa^1^, S. Yuan^2^, A. Talla^3^, A.G. Bebein-Blackwell^4^, J. Brehm^5^, R. Barnard^6^, M. Miller^6^, D. Hazuda^6^, N. Chomont^7^, R.P. Sékaly^3^

^1^Southern Research Institute, Frederick, MD, USA, ^2^Janssen Pharmaceuticals, Springhouse, PA, USA, ^3^Case Western Reserve University, Cleveland, OH, USA, ^4^University of Georgia, Athens, GA, USA, ^5^GlaxoSmithKline, Raleigh, NC, USA, ^6^Merck, West Point, PA, USA, ^7^Université de Montréal, Montreal, QC, Canada

HIV persists in individuals on antiretroviral therapy in central memory (CM), transitional memory (TM) and effector memory (EM) CD4+ T cells. Development of "shock and kill" strategies to eradicate the persistent HIV reservoir will depend on the ability to predict the responsiveness of each subset to latency-reversing agents (LRAs) in this heterogeneous population. To examine the contribution of each subset to latency reactivation, we developed a primary cell based assay that models the latent reservoir in virally suppressed HIV-infected subjects. Our **l**atency **a**nd **r**eversion **a**ssay (LARA) is based on infection of minimally activated CD4+ T cells and employs TGF-β, an inducer of T cell quiescence, and IL-7, an inducer of T cell survival and homeostatic proliferation, to efficiently establish HIV latency in CM, TM, and EM subsets. These conditions allow for the simultaneous assessment of HIV latency reversion in all subsets in a single assay. Using LARA, we demonstrate that all memory CD4+ T cell subsets are capable of robust latency reversion following TCR engagement (αCD3/CD28). Other classes of compounds such as PKC agonists, HDAC inhibitors, and γc cytokines demonstrated a diverse capacity to reverse latency in the different memory subsets. When compared to the response achieved from maximal TCR stimulation, compounds such as disulfiram could reverse latency effectively in CM (\~72% of αCD3/CD28 signal) or TM (\~95%), but had reduced efficiency in EM (\~30%), whereas IL-15 was more efficient in EM (\~64%) and TM (\~56%), while CM were minimally responsive (\~13%). Together these data support the significance of the biological diversity of memory CD4+ T cell subsets in their ability to respond to LRAs. We present LARA as an optimized platform for measuring the activity of LRAs in CD4+ T cell memory subsets that are known to contribute to the latent HIV reservoir *in vivo*, which will result in a streamlined process to advance candidate LRAs for future clinical use.
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OP 1.6

Quantifying the impact of autologous transplantation on viral reservoirs in a nonhuman primate model of HIV/AIDS

C.W. Peterson^1^, C. Benne^2^, P. Polacino^3^, A. Baldessari^4^, R.D. Murnane^4^, S.L. Hu^3^, R. Sekaly^2^, H. Kiem^1,3^

^1^Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ^2^Case Western Reserve University, Cleveland, OH, USA, ^3^University of Washington, Seattle, WA, USA, ^4^Washington National Primate Research Center, Seattle, WA, USA

**Background:** Hematopoietic stem cell (HSC) gene therapy holds great promise in the cure of HIV infection, but the feasibility of this approach in stably suppressed patients remains unclear. We are evaluating gene therapy approaches to reduce or eliminate viral reservoirs in a pigtailed macaque model of drug-suppressed HIV infection.

**Methods:** Animals are challenged with HIV enveloped simian/human immunodeficiency virus (SHIV), and suppressed by three-drug combination antiretroviral therapy (cART). During autologous transplantation, myeloablative total body irradiation (TBI) is used to increase engraftment of subsequently infused HSCs, and to target latently infected cells. Immunological and viral reservoir assays are conducted in peripheral blood and tissues from animals transplanted with engineered and non-engineered HSCs, as well as untransplanted controls.

**Results:** TBI leads to a drastic reduction in circulating CD4+ T-cell counts. Consistent with past reports, SHIV viremia rebounds following cART withdrawal in animals that are transplanted without a protective gene therapy approach. Early viral reservoir analyses suggest that persistent reservoir sites are seeded in these animals, and are impacted by the transplant procedure. Flow cytometry data reveal differential expression of markers including PD-1, SLAM, and TIGIT in transplanted animals relative to untransplanted controls.

**Conclusions:** Although autologous transplantation is known to be insufficient for viral eradication, we demonstrate that this procedure does modulate viral reservoirs. TBI significantly reduces the number of CD4+ memory T-cells, but may enhance viral rebound if cART is withdrawn prior to complete hematologic recovery. Our preclinical model allows not only for the evaluation of novel gene therapy and gene editing approaches to impact the latent viral reservoir, but also combinatorial approaches, which may include therapeutic vaccination, immune modulators, and/or latency reactivating agents.
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OP 2.0

HIV-1 transcriptional latency in resting CD4 T-cell

M. Benkirane

CNRS, Montpellier, France

Abstract not available at the time of printing
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OP 2.1

Single-cell analysis identifies biomarkers for HIV permissiveness

A. Ciuffi^1^\*, S. Quenneville^1^\*, A. Rausell^1,2^\*, S. Rato^1^, M. Muñoz^1^, A. Telenti^3^\*

^1^Institute of Microbiology, University of Lausanne, Switzerland, ^2^Vital-IT Group, Swiss Institute of Bioinformatics, Lausanne, Switzerland, ^3^J Craig Venter Institute, La Jolla, CA, USA

**Background:** Cellular permissiveness to HIV infection is highly heterogeneous across individuals. Heterogeneity is also found across CD4+ T cells from the same individual, where only a fraction of cells gets infected. We used a single-cell RNA-Seq approach to investigate cellular heterogeneity and identify biomarkers of HIV permissiveness.

**Methods:** CD4+ T cells from healthy donors were activated by TCR-mediated stimulation for three days and tested for their permissiveness to HIV infection. Non-infected activated CD4+ T cells from a highly and a poorly susceptible individual were selected and used for single-cell RNA-Seq analysis using Fluidigm C1 technology.

**Results:** RNA-Seq profiles from 85 highly permissive and 81 poorly permissive single cells were successfully obtained, with \~25 million reads per single cell. Transcriptional heterogeneity translated in a continuum of intermediary cell states in both highly and poorly permissive donor cells, which was mainly driven by TCR-mediated cell activation. Genes whose expression was bimodal across cells, across both donors and that encoded proteins expressed at the cell surface were further investigated as candidate biomarkers of HIV permissiveness. Seven single biomarkers were tested for their ability to capture permissive cells, showing enrichment in HIV infection from 1.5- to 10-fold. The combination of multiple candidate biomarkers further selected for highly permissive cells, thus defining the "HIV-permissive cell". This held true in CD25-sorted subpopulations as wells as in naive or memory CD4+ T cell subsets.

**Conclusions:** Our data identified activation as a major determinant driving cellular heterogeneity in HIV permissiveness and further revealed the role of single candidate biomarkers in defining the HIV highly permissive cell. The single-cell-based approach developed in this study should help characterizing the heterogeneity of the HIV latent reservoir, as well as its response to reactivating agents.
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OP 2.2

Cellular HIV RNA/DNA as biomarkers of inducible virion production

A. Cillo^1^, F. Hong^1^, A. Tsai^2^, A. Irrinki^2^, J. Kaur^2^, J. Lalezari^3^, D. Sloan^2^, J.P. Murry^2^, J. Mellors^1^

^1^University of Pittsburgh, Pittsburgh, PA, USA, ^2^Gilead Sciences, Foster City, CA, USA, ^3^Quest Clinical Research, San Francisco, CA, USA

**Background:** Simple biomarkers of the inducible HIV reservoir have not been identified. We investigated whether the frequency of infected cells in blood and their transcriptional activity is related to the inducible HIV reservoir from resting CD4+ T cells in persons on antiretroviral therapy (ART).

**Methods:** PBMC were isolated from leukapheresis product obtained from donors on suppressive ART for ≥1 year. Cellular unspliced HIV RNA (CA-RNA) and proviral HIV DNA (CA-DNA) in uncultured PBMC were quantified by qPCR. Resting CD4+ T (rCD4) cells were isolated from PBMC by negative selection, and were then activated with PMA/ionomycin in the presence of 300 nM efavirenz. On day 6 of culture, supernatants were collected, centrifuged (500×*g* for 5 min), and stored at −80°C. HIV RNA in supernatants was quantified by COBAS Roche TaqMan v2.0. Correlations between virion production and cellular HIV RNA/DNA were assessed using Spearman\'s correlation coefficient.

**Results:** A total of 22 donors were evaluated. Levels of HIV-1 RNA after treatment with PMA/ionomycin varied \>1000 fold between donors; the median was 4406 copies/mL of culture supernatant, ranging from 38 to 42,756 copies/mL. The median level of CA-RNA was 38 (range: \<1--355) copies per 10^6^ PBMC, and the median level of CA-DNA was 286 (range: 7--2972) copies per 10^6^ PBMC. CA-RNA and CA-DNA levels were strongly correlated with each other (rho=0.80, *P*\<0.001), and both were strongly correlated with inducible virion production (rho=0.76, *P*\<0.001 for CA-RNA; rho=0.75, *P*\<0.001 for CA-DNA).

**Conclusions:** Inducible virion production from rCD4 cells *ex vivo* is strongly associated with the number of HIV-infected cells and the basal level of HIV-1 RNA transcription in PBMC. These results suggest simple measures of CA-RNA/DNA can be used to estimate the size of the inducible reservoir. These approaches could also be useful in assessing the effectiveness of interventions targeting the latent HIV reservoir. These approaches could also be useful in assessing the effectiveness of interventions targeting the latent HIV reservoir.
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OP 2.3

The HIV-1 antisense transcript AST is an inducer of viral latency

F. Romerio^1^, J.C. Zapata^1^, F. Kashanchi^2^, S. Iordanskyi^2^

^1^Institute of Human Virology, Baltimore, MD, USA, ^2^George Mason University, Manassas, VA, USA

**Background:** Noncoding RNAs (ncRNAs) regulate gene expression by recruiting chromatin-modifying enzymes to the gene\'s promoter. EZH2, a histone methytransferase part of the Polycomb Repressor Complex 2 (PRC2), trimethylates lysine 27 in histone H3 at the proviral 5′LTR, which positions Nuc-0 and Nuc-1 and leads to latency. How are Nuc-0 and Nuc-1 precisely and invariably positioned at the 5′LTR irrespective of the site and orientation of HIV-1 integration in the host genome? What ncRNA recruits PRC2 to the 5′LTR? An attractive hypothesis is that HIV-1 encodes for its own ncRNA as an autonomous mechanism to recruit PRC2 to the 5′LTR, and to establish latency regardless of the surrounding chromatin context. Indeed, HIV-1 expresses an antisense transcript (AST) directed from a poorly defined promoter within the 3′LTR.

**Methods:** We developed a strand-specific quantitative RT-PCR assay to measure AST expression in infected cells. We generated cell lines stably transduced with AST, and tested the effect of AST on HIV-1 replication and latency. We performed ChIP assays to test whether AST affects the pattern of chromatin assembly at the 5′LTR. We performed RIP assays to test whether AST interacts with PRC2.

**Results:** AST is expressed in chronically infected cell lines, primary CD4+ T cells infected *in vitro*, and CD4+ T cells from patients under cART. Expression of AST suppressed HIV-1 replication, and promoted the establishment and maintenance of latency. This correlated with decreased levels of RNA Pol II, and increased levels of H3K27me3 and HDAC at the 5′LTR. In addition, we found direct interaction between AST and PRC2.

**Conclusions:** The 3′LTR directs the expression of an antisense transcript (AST), which recruits PRC2 to the 5′LTR, and promotes epigenetic modifications that lead to viral latency. Thus, AST is a virally encoded ncRNA that acts as an inducer of viral latency. These results could guide in designing new therapies aimed at stabilizing latency by exploiting AST.
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OP 2.4

Integration site analysis of latently infected cell lines: evidence of ongoing replication

J. Symons^1^, S.R. Lewin^1,5^, A. Chopra^2^, E. Malantinkova^3^, W. De Spiegelaere^3^, S. Leary^2^, D. Cooper^2^, L. Vandekerckhove^3^, S. Mallal^2,4^, P. Cameron^1,5^

^1^Peter Doherty Institute for Infection and Immunity, University of Melbourne, Australia, ^2^Institute for Immunology and infectious diseases (IIID), Murdoch University, Perth, Australia, ^3^HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium, ^4^Department of Infectious Diseases, Vanderbilt University, Nashville, TN, USA, ^5^Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia

**Background:** HIV cure is limited by persistence of long lived latently infected CD4+ T cells. Latently infected cell lines are widely used *in vitro* to study HIV latency. We identified and tested the stability of HIV integration sites in latently infected cell lines, using a newly developed high throughput method.

**Method:** To determine assay sensitivity/efficiency, genomic DNA of seven latent HIV cell lines (20 cells each) were isolated and mixed with genomic DNA from one million HIV negative PBMCs. Additionally, the latently infected cell lines ACH-2, U1 and J1.1 containing replication competent HIV and J-Lat 8.4, 9.2, 10.6 and 15.4 cell lines that contain a single replication deficient HIV were passed. DNA, isolated after passage 0, 2, 4, 6 and 8 was enzymatically cut to random sized fragments. These were end-repaired and a linker was ligated to the fragments. The fragments were subjected to LTR based nested PCR with barcoded nested primers and prepared for Miseq sequencing. Chromosomal alignment was determined using the Blat-UCSC Genome Browser (GRCH38/hg38).

**Results:** The efficiency was 35% and detected one HIV integration site in 50,000 uninfected PBMCs. J-Lat cell lines showed single integration sites. ACH-2, U1 and J1.1 demonstrated multiple distinct HIV integration sites per 150,000 cells (74, 42 and 93 respectively). J1.1, which is reported to have a single integrated copy per cell, demonstrated two major integration sites in equal frequency. ACH-2 cells, when passaged, demonstrated a 2-fold increase in unique HIV integration sites found across the human genome.

**Conclusion:** Cell lines latently infected with replication competent HIV demonstrated multiple unique HIV integration sites indicating these cell lines are not clonal. Furthermore, the increase and change in sites of HIV integration observed in ACH-2 cells over time is suggestive of low level virus replication. These findings have implications for the use of latently infected cell lines as models of HIV latency.
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OP 2.5

Mixed effects of HDACi on host gene expression and their implications for HIV reactivation from latency

N. Beliakova-Bethell^1,2^, A. Mukim^2^, S. Deshmukh^2^, C.H. White^3^, C.H. Woelk^4^, C.A. Spina^2,5^

^1^Department of Medicine, University of California San Diego, La Jolla, CA, USA, ^2^VA San Diego Healthcare System, San Diego, CA, USA, ^3^Graduate Program in Bioinformatics and Systems Biology, University of California San Diego, La Jolla, CA, USA, ^4^Faculty of Medicine, University of Southampton, UK, ^5^Department of Pathology, University of California San Diego, La Jolla, CA, USA

**Background:** Previously, we identified transcriptomic and proteomic effects of the HDACi SAHA, associated with promotion or inhibition of HIV reactivation. Here, we have further characterized these effects in primary CD4+ T cells of various maturation phenotypes and compared them with those induced by another HDACi, romidepsin (RMD).

**Methods:** A unique model was used to generate latent HIV infection in resting primary CD4+ T cells. Cells were treated for 24 h with SAHA (1 μM), RMD (15 nM), or their solvent dimethyl sulfoxide. Naïve (T [n]{.smallcaps}), central (T [cm]{.smallcaps}), and effector memory (T [em]{.smallcaps}) cells were isolated by flow cytometry cell sorting. Differential gene expression analyses were performed using RNA-Seq and *EdgeR* package in Bioconductor R.

**Results:** Similar to SAHA, RMD induced gene expression changes that could be interpreted to promote or inhibit HIV reactivation. However, several RMD effects were consistent with the idea that it may be a more potent activator of HIV expression (downregulation of HIV transcriptional repressors *AES* and *ARID1B* to a greater extent, and upregulation of other repressors, *HMGA1* and *ASF1A,* to a lesser extent, than SAHA). Results from CD4+ T cell maturation subsets indicated that SAHA may be a more potent activator of HIV provirus from T [n]{.smallcaps} cells. For example, *AES* was downregulated to a greater extent in T [n]{.smallcaps} cells; while a gene encoding heat shock protein, required for proper folding of cyclin T1/Cdk9, was upregulated to a greater extent in T [n]{.smallcaps}, as compared to T [cm]{.smallcaps} and T [em]{.smallcaps} cells.

**Conclusions:** These results may provide clues to the ineffectiveness of HDACi to clear the HIV reservoir in clinical trials. HDACi exhibit both inductive and inhibitory effects on HIV reactivation in CD4+ T cells. In addition, HDACi may be most active in T [n]{.smallcaps} cells, the minority component of the latent reservoir. Combination treatment strategies will be required to counteract inhibitory effects and ensure efficient viral reactivation from CD4+ T cells regardless of maturation state.
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OP 2.6

HIV-1 latency is established preferentially in minimally activated and non-dividing cells during productive infection of primary CD4 T cells

C.A. Spina^1,2^, P.C. Soto^1,2^, V.H. Terry^1^, M.K. Lewinski^3^

^1^Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, ^2^Department of Pathology, University of California San Diego, La Jolla, CA, USA, ^3^Department of Medicine, University of California San Diego, La Jolla, CA, USA

**Background:** The primary barrier to HIV eradication is establishment of a stable reservoir of latently infected CD4 T cells very early in the course of infection that leads to life-long viral persistence. The mechanisms involved in establishment of this reservoir remain unclear. Three scenarios have been proposed: (1) activated proliferating cells become infected and revert back to quiescence; (2) activated cells become infected, while returning to a resting state; or (3) infection is established directly in resting cells.

**Methods:** To determine the phase of T cell activation at which acute infection is most likely to progress to latency, two approaches were used. First, cells were infected at different times, before or after stimulation by anti-CD3/CD28, and followed out to 14 days when cells had returned to resting. Second, cell proliferation of acutely infected cultures was tracked using CFSE dye and cell subsets that had undergone varying degrees of proliferation were isolated by FACS, at the end of culture. Each recovered cell subset was analyzed for the quantity of integrated HIV DNA and replication-competent virus.

**Results:** Cells exposed to HIV, prior to stimulation, contained the highest levels of integrated provirus and replication competent virus after returning to quiescence. Cells infected, during the height of cell proliferation, retained the least HIV. Cells that did not divide or divided only a few times contained higher levels of integrated and replication-competent HIV than did cells, which had divided many times.

**Conclusions:** HIV latency is established very early within a heterogeneous population of CD4 T cells, which are undergoing varying degrees of cell activation in the presence of infectious virus. Minimally activated cells within this milieu are the most likely to develop persistent latent infection. These observations have important implications for the study of latency, and may aid in the design of strategies to purge this reservoir.
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OP 3.0

The virology of HIV-1 persistence: integration, expansion, and expression

J. Coffin

Tufts University School of Medicine, Boston, USA

Abstract not available at the time of printing
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OP 3.1

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency

B.J. Howell, G. Wu, M. Swanson, M. Lu, D.J. Graham, J. Strizki, S. Wolkenberg, R.J.O. Barnard, W. Blair, D.J. Hazuda

Merck, West Point, PA, USA

**Background:** Novel approaches are being explored for eradicating HIV from tissue/cell reservoirs, and new assays with improved sensitivity are required to quantify reservoir size and examine the impact of latency-reversing agents on actively replicating virus following "flush-kill" strategies. Towards this goal, a highly sensitive digital immunoassay was optimized to quantify HIV p24 capsid protein in culture medium and cell lysates and can be used as a biomarker for evaluating viral protein production following perturbation of HIV latency state.

**Methods:** A commercial immunoassay was optimized to improve assay sensitivity and specificity and to quantify p24 in both cell lysates and culture medium. Viral supernatants from 18 genotypically diverse HIV isolates (including, HIV-2, HIV-1, subtypes A, B, C, D, E, G and group O) were serially diluted and evaluated. Quantification of p24 from CD4+ T cells isolated from ART suppressed HIV patients was determined following *ex vivo* treatment with latency-reversing agents, including PMA/Ionomycin and HDAC inhibitors. Kinetics of p24 expression were evaluated and confirmed.

**Results:** The optimized p24 immunoassay specifically recognized both recombinant p24 and uncleaved polyprotein p55 with equal affinity. The lowest limit of reliable quantitation in cell lysate and cultured medium was determined to be 14 fg/mL. p24 was detected and showed specificity and linear dilution across 18 clinical isolates. *Ex vivo* treatment of CD4+ T cells from ART suppressed patients with latency-reversing agents, including PMA/Ionomycin and HDAC inhibitors, showed robust, dose-dependent and time-dependent changes in p24 in cell lysates and culture medium.

**Conclusions:** The optimized, p24 immunoassay shows \~2000 fold increased sensitivity over gold-standard p24 assays and can quantify viral protein in cell lysates and culture medium from ART suppressed patient cells. HDACi treatment of resting CD4+ T cells from ART suppressed patients results in viral protein production in a dose- and time-dependent manner. The assay has potential to be used for rapid, sensitive detection of p24 in HIV latency studies.
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OP 3.2

Detection and enrichment to near purity of rare HIV-1 infected cells by PrimeFlow RNA

F. Romerio, J.C. Zapata

Institute of Human Virology, Baltimore, MD, USA

**Background:** PrimeFlow RNA is a technique that detects RNA molecules by flow cytometry, generating gene expression data at the single cell level. Sets of 20--40 probe pairs hybridize to the target RNA. Signal amplification and detection is achieved by branched DNA (bDNA) via hybridization of adjacent probe pairs with pre-amplifiers, amplifiers and fluorochrome-conjugated label probes. This yields low background, high specificity and high signal-to-noise ratio. In PrimeFlow RNA, detection occurs through amplification of signal (up to 8,000×) rather than target sequence (PCR) for more consistent results. PrimeFlow RNA can be combined with detection of protein markers by traditional flow cytometry.

**Methods:** We developed three different probe sets for the detection of full length, single-spliced, or multiply spliced HIV-1 transcripts. We have used these probe sets (alone or in combination) for the detection and isolation of infected cells.

**Results:** All three HIV-1 specific probe sets detected productively infected cells, but not uninfected or latently infected cells. Through the combination of two HIV-1 specific probe sets labeled with different fluorochromes, we specifically detected infected cells mixed with uninfected cells at ratios as low as 10--100 infected cells per 10^6^ uninfected cells. This technique allowed accurate enumeration of infected cells. In addition, we were able to sort the infected cells at purities \>90% as assessed by qPCR of HIV-1 *vs.* GAPDH DNA copy numbers.

**Conclusions:** PrimeFlow RNA detects and accurately enumerates infected cells present in mixed populations at dilutions that are in the same range as those of latently infected cells in clinical samples. In addition, PrimeFlow RNA allows sorting these cells to near homogeneity. This technique may be useful to identify, enumerate and phenotype latently infected cells from cART-suppressed individuals after viral reactivation.
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OP 3.3

Sustained HIV release by single persisting CD4+ T cells during latency disruption

J.M. Hataye, J.P. Casazza, D.R. Ambrozak, E. Boritz, T. Yamamoto, D.C. Douek, A.S. Perelson, R.A. Koup

National Institutes of Health, Vaccine Research Center, Bethesda, MD, USA

**Background:** While the dynamic details of HIV release from the source CD4+ T cells undergoing latency disruption are unknown, both multi-day sustained HIV release and instantaneous burst stochastic models of HIV replication have been proposed. Which model best represents latency disruption may have important implications for detecting replication-competent virus.

**Methods:** We used HIV *gag* RNA RT-PCR to quantify HIV release from isolated primary CD4+ T cells undergoing latency disruption. Limiting dilution viral inhibition cultures with efavirenz revealed released virus without new rounds of infection and were compared to respective outgrowth cultures. Stochastic models were implemented using the Gillespie algorithm with parameters derived from applying the deterministic model to experimental data.

**Results:** While many outgrowth wells accumulated high amounts of virus, many had declining virus that was nevertheless replication-competent, confirmed by virus transfer to new outgrowth wells. Culture wells with \>77% probability of being seeded by a single virus-producing cell were analyzed for viral release. Half of cells releasing virus did so within 4 days. The accumulated virus for a well varied from less than 120 to 30,000 HIV *gag* RNA copies. Although a low amplitude instantaneous burst pattern was observed, the vast majority of accumulated HIV RNA was attributed to a higher amplitude virus release sustained for 2--6 days. The half-life of virus in viral inhibition cultures was 3 days. Applying this result to the deterministic model, we estimated an average total sustained release per cell of 5500 HIV RNA copies.

**Conclusions:** Our results are consistent with a multi-day sustained virus release stochastic model that predicts replication-competent virus will be present in cultures that are negative for viral outgrowth, and further demonstrate that single virus-producing cells can survive and produce virus over several days without succumbing to viral cytopathic effects.
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OP 3.4

Antiretroviral drug activity in macaque PrEP breakthrough infections has only a transient effect on cell-associated SHIV DNA reservoirs

J.G. García-Lerma, M.E. Cong, C.P. Pau, W. Heneine

Centers for Disease Control and Prevention, Atlanta, GA, USA

**Background:** Infection of macaques with simian HIV (SHIV) during concurrent pre-exposure prophylaxis (PrEP) with FTC/TDF is associated with reduced acute plasma viremias and limited virus diversity, thus providing a unique model to assess long-term effects of acute antiretroviral treatment. Here, we investigated the effect of PrEP on acute SHIV DNA dynamics in peripheral blood mononuclear cells (PBMCs), and on the size of the persistent virus reservoir in lymphoid tissues.

**Methods:** Cell-associated SHIV DNA levels were measured in PBMCs during acute infection in 8 macaques infected during concurrent PrEP with FTC/TDF combination or single-agent tenofovir alafenamide fumarate (TAF). Macaques continued treatment with 1--2 weekly drug doses to model suboptimal drug exposure during undiagnosed HIV infection in humans. Peak SHIV DNA and area under the curve values (AUC) over 5 or 20 weeks, as well as RNA levels, were compared to the values seen in untreated SHIV infections (*n*=10). SHIV DNA levels were also measured in lymphoid tissues collected from FTC/TDF or maraviroc PrEP breakthroughs after 1 year of infection.

**Results:** PrEP breakthrough infections had reduced plasma RNA viremias relative to untreated infections both at peak and during the first 20 weeks of infection (*P*\<0.005). SHIV DNA levels in PBMCs were also reduced in PrEP breakthrough infections both at peak and at week 5 (*P*=0.022 and *P*=0.043, respectively), but not after 20 weeks of infection. At 1 year, SHIV DNA reservoirs in lymphoid tissues were similar in size among macaques that received PrEP with FTC/TDF (median=464 SHIV DNA copies/10^6^ cells; range, 40--5,346), PrEP with maraviroc (median=1088 copies/10^6^ cells; range, 554--10,090), or placebo (median = 952 copies/10^6^ cells; range, undetectable--24,668) (*P*\>0.05).

**Conclusions:** Antiviral drug activity due to PrEP limits acute SHIV replication but has only a transient effect on cell-associated DNA levels in PBMCs and lymphoid tissues. Our model suggests that suboptimal drug exposure in persons that are taking PrEP and become infected with HIV may not be sufficient to reduce the pool of HIV-infected cells, and that treatment intensification may be needed to sustain the virologic benefit from the PrEP regimen.
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OP 3.5

*In vivo* expression of unspliced HIV RNA in expanded CD4+T-cell clones containing defective or replication-competent proviruses

M.F. Kearney^1^, J. Spindler^1^, M. Sobolewski^2^, J.M. Coffin^3^, J.W. Mellors^2^

^1^HIV Dynamics and Replication Program, Department of Medicine, National Cancer Institute, Frederick, MD, USA, ^2^University of Pittsburgh, Pittsburgh, PA, USA, ^3^Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, USA

**Background:** Clonal expansion of HIV infected cells is an important mechanism for viral persistence during ART and cells that express unspliced HIV RNA (usRNA) may lead to rebound viremia when ART is interrupted. We investigated the proportion of proviral populations that express usRNA in ART-treated individuals and the fraction that can produce replication-competent virus.

**Methods:** PBMCs from five donors on ART for \>5 years and with levels of viremia \<20 copies/mL were analyzed for expression of usRNA using SGS of cell-associated RNA (CAR-SGS) and DNA (CAD-SGS). CAR-SGS was performed by extracting RNA from multiple PBMC aliquots per sample after diluting to an endpoint for HIV expressing cells. cDNA was synthesized from each RNA extraction and analyzed by gag-pol SGS. DNA was extracted from 1 PBMC aliquot to compare the genetics of CAR to CAD (CARD-SGS) and to quantify the number of pol-containing proviruses using real-time PCR. Identical CAD or CAR sequences across aliquots indicated the presence of clonally expanded populations. Infectious proviruses were detected by VOA performed on CD4+T-cells from the same ART-suppressed individuals and infectious proviruses were related to CAR-SGS via sequencing of gag-pol.

**Results:** Levels of pol-containing proviruses ranged from 103*--*874/10^6^ PBMCs of which a median of 8% (4--12%) were found to express usRNA. All five donors had detectably expanded proviral clones (median \>9 clonal populations per donor). A median of at least 13% (5--21%) of the expanded proviruses detected by CAD-SGS were found to express usRNA. However, of the 25 distinct infectious variants isolated by VOA and the 302 distinct CAR sequences identified, only one match was found (0.3%), suggesting that almost all clonal populations expressing usRNA are defective.

**Conclusions:** Although expanded proviral populations in individuals on ART often express usRNA, most appear to be defective. Rarely, they can be replication-competent and thus serve as a reservoir for HIV rebound.
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OP 4.0

Tissue localization of human T cell responses

D. Farber

Columbia University Medical Center, New York, USA

Abstract not available at the time of printing
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OP 4.1

Proliferation of perivascular macrophages in macaque models of lentiviral encephalitis: a potential mechanism for HIV/SIV persistence in the brain

W.K. Kim, A.R. Filipowicz, C.M. McGary, G.E. Holder, M.J. Kuroda

Eastern Virginia Medical School, Norfolk, VA, USA

In lentiviral encephalitis, the number of brain perivascular macrophages (PVM) is substantially increased. This may be due to recruitment of precursors from peripheral blood and/or *in situ* proliferation in the central nervous system (CNS). While the former possibility has been explored, research into the latter is lacking. We therefore investigated if macrophage proliferation occurs in the CNS during simian immunodeficiency virus (SIV) infection of adult macaques. Using immunohistochemistry and fluorescence microscopy, we examined the expression of proliferation markers including Ki-67 and incorporation of thymidine analogs by PVM in the brains of uninfected macaques and SIV-infected macaques with or without encephalitis. Double-label immunohistochemistry using antibodies against the pan-macrophage marker CD68 and Ki-67 showed that there was a significant increase in Ki-67+CD68+ cells in macaques with SIV encephalitis (SIVE) compared to uninfected controls and SIV-infected animals without encephalitis (SIVnoE). Multi-label immunofluorescence against CD163 (PVM marker) and Ki-67 with a nuclear counterstain confirmed that the vast majority of Ki-67+ nuclei were localized to CD163+ PVM in perivascular cuffs and lesions that characterize SIVE. The proliferative capacity of Ki-67+ PVM was confirmed by their nuclear incorporation of bromodeoxyuridine (BrdU) and 5-ethynyl-2′-deoxyuridine. Using combinations of the macrophage markers CD16, CD68, and CD163 with the proliferation markers BrdU and Ki-67 revealed that multinucleated giant cells (MNGC) also displayed a proliferative capacity. Examining the MNGC and SIVE lesions further, using double-label immunofluorescence with antibodies against Ki-67 and SIV Gag p28, showed that not only were the Ki-67+ cells productively infected, but that there was a significant positive correlation between the size of lesions and the number of Ki-67+ cells in these lesions. Altogether, this study shows that there are subpopulations of macrophages that both express proliferation markers and are SIV-infected in the brain, suggesting a mechanism of SIV persistence and accumulation in the CNS via PVM proliferation.
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OP 4.2

The human lung is a site of productive HIV infection during long-term ART: novel tools to study ART-durable HIV reservoirs

D.W. Gludish^1^, H.C. Mwandumba^2^, K.C. Jambo^2^, S.M. Amie^1^, D.G. Russell^1^

^1^Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA, ^2^Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi, College of Medicine, Blantyre, Malawi

**Background:** Tuberculosis is the leading cause of death among HIV-infected individuals, most notably in Sub-Saharan Africa. We developed novel tools to probe HIV biology in the lungs of Malawian adults to understand this susceptibility that persists even during ART. Our previous work found HIV mRNA in alveolar macrophages (AMs) of HIV patients. To determine if AMs produce infectious HIV, we sought a robust, rapid readout amenable to flow cytometry at point of care.

**Methods:** JC53 HeLa cells (express CD4, CCR5 and CXCR4) were modified to express GFP dependent on HIV Tat and Rev (TZM-GFP). In laboratory co-cultures with HIV-infected human monocyte-derived macrophages (HMDMs), we observed clear GFP induction in TZM-GFP. We showed by limiting dilution that TZM-GFP cells can report a single infected HMDM in 96-well co-culture, facilitating viral outgrowth assays to quantify cells that harbor infectious provirus. We then co-cultured TZM-GFP with bronchoalveolar lavage (BAL) cells from asymptomatic HIV-positive adults at the Queen Elizabeth Hospital, Blantyre, Malawi: GFP protein and HIV gag mRNA were assayed by fluorescent *in situ* hybridization (FISH) and flow cytometry.

**Results:** FISH analysis of BAL cells indicated that viral mRNA was found predominantly in AMs at HIV diagnosis. This AM signal was also found in aviremic individuals on ART, suggesting persistence of HIV in AMs despite successful therapy. Similarly, BAL cells from ART-treated and ART--naïve patients induced GFP in TZM-GFP co-cultures. The transfer of infectious virus was validated by HIV mRNA FISH.

**Conclusions:** (1) ART, though successful in clearing viremia, spares HIV-infected AMs. (2) BAL cells from ART-treated patients generate infectious virus, showing the lung is a site of HIV maintenance. (3) HIV in the lung is mainly found in AMs, a potential anatomical reservoir that remains understudied. This study reports on the lung as a site of viral persistence and productive infection in the face of effective ART.
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OP 4.3

Lymphatic and cancer tissues are a potential reservoir of replicating virus in virally suppressed ART+ patients

R. Rose^1^, S.L. Lamers^1^, D.J. Nolan^1,2^, M.S. McGrath^3^

^1^Bioinfoexperts, LLC, Thibodaux, LA, USA, ^2^Department of Pathology, Immunology, and Laboratory Medicine, Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA, ^3^AIDS and Cancer Specimen Resource and the Department of Laboratory Medicine, Medicine and Pathology, University of California at San Francisco, CA, USA

**Background:** Antiretroviral therapy (ART) is effective in reducing plasma HIV loads to undetectable levels. However, HIV can rapidly rebound once therapy is removed. Furthermore, HIV-associated co-morbidities, particularly certain cancers, remain a significant co-morbidity even with effective ART. We hypothesized that HIV-infected macrophages in tumors may both protect HIV from ART and contribute to metastasis.

**Methods:** The ACSR provided 36 post mortem tissues from five HIV+/ART+ patients with no detectable viral load. All five (designated Pt1--5) died with a form of metastatic cancer. Tissues were assessed for HIV using digital droplet PCR (ddPCR). Single genome sequencing was used to generate *env*-*nef* DNA and RNA sequences. Maximum-likelihood phylogenies were inferred and statistical tests were performed to investigate viral evolutionary patterns and compartmentalization. An *in situ* RNA signal detection technique (RNAscope) combined with histological staining was used to visualize the cellular location of HIV in select tissues.

**Results:** All tissues were HIV+ by ddPCR. HIV *env-nef* DNA sequences were generated from 21/36 of the tissues, and a much smaller subset of these (*n*=5) contained both HIV RNA and DNA. Maximum-likelihood phylogenies and statistical testing showed little evidence of viral compartmentalization among tissues. Tree clades showed evidence of on-going evolution as well as clonal expansion. RNAscope for *Pt02* showed HIV RNA co-localizing with CD163+/CD68+ macrophages in tumor lymph node and, in the cerebellum, with infected cells surrounded by infiltrating macrophages.

**Conclusions:** Results suggest that cancer tissues may offer a privileged environment for persistent HIV replication within macrophages during ART. Two distinct patterns of virus evolution suggest different modes of replication/spread underlie persistence: ART-resistant HIV-infected macrophages with persistent evolution and migration of HIV infected cells that clonally expand.
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OP 4.4

Immunological properties of testicular tissue as an anatomical reservoir in ART-treated HIV-infected adults

J.P. Routy^2,6^,M.A. Jenabian^1^, J. Brousseau^1^, K. Vyboh^2^, F.M. Ghazawi^1,3^, P. Brassard^4^, M. Bélanger^4^, N. Chomont^5^, P. Ancuta^5^

^1^Department of Biological Sciences and BioMed Research Centre, Université du Québec à Montréal (UQAM), Canada, ^2^Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Canada, ^3^Faculty of Medicine, McGill University; ^4^Metropolitan Centre for Plastic Surgery, Montréal, Canada, ^5^Université de Montréal, Faculté de Médecine, Département of microbiologie, infectiologie et immunologie and Centre de recherche du CHUM, Montreal, Canada, ^6^Division of Hematology, McGill University Health Centre, Canada

**Background:** As human testis is an immune privileged site that represents an anatomical viral reservoir, we assessed its immunological properties in HIV-infected adults on suppressive ART.

**Methods:** Testicular tissue and blood were collected from virally suppressed adults (*n*=6) on ART for at least 6 months prior to gender reassignment surgery and controls (*n*=10). T-cells were purified by CD3 microbeads from freshly isolated testicular interstitial cell suspensions. T-cell subsets, immune activation cell markers and mRNA expression were assessed by cytometry and RT-PCR.

**Results:** Lower CD4 T-cell proportion among total T-cells was found in testis *vs.* blood in both VIH+ and HIV- groups. A decrease in naive and an increase in effector-memory (EM) T-cell subsets were observed in testis *vs.* PBMCs of both groups. Importantly, up to 77-fold increases in CCR5 expression were observed on testicular T-cells when compared to PBMCs. Increased T-cell immune activation (CD38/HLA-DR) in testis was observed only in HIV+ group, while immunoregulatory soluble CD38 was lower in testis. Elevated Th2 and Th17 and lower Th1 cell expression was observed in testis. Global Treg population and FoxP3 expression were similar in testis and blood. Interestingly, higher frequencies of immunosuppressive CD39+ Tregs were found in testis of both groups *vs.* blood. A massive increase in testicular CD73 expression, notably on memory CD8 T-cells *vs.* blood was also observed in both groups. A remarkable increase in both IDO-1 and IDO-2 immunosuppressive enzymes was observed in testis *vs.* blood.

**Conclusion:** We observed an increase in EM T-cell frequency, CCR5 expression and immunosuppressive enzymes CD39/CD73 and IDO-1/-2 in testis *vs.* blood regardless of HIV status. ART-treated adults had elevated levels of testicular T-cell immune activation compared to HIV- controls. These findings demonstrate the immune tolerance properties in testicular tissue representing a distinctive anatomical reservoir for HIV persistence.
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OP 4.5

Persistence of HIV-infected alveolar macrophages after suppressive ART

F.F. Hong, H. Michael, S. Qin, L.A. Kingsley, D.D. McMahon, M.E. Fitzpatrick, A.M. Morris, J.W. Mellors

University of Pittsburgh, PA, USA

**Background:** No conclusive evidence is available for long-term persistence of HIV infection in macrophages during suppressive ART. We analyzed highly purified alveolar macrophages (AM) for HIV infection and transcriptional activity *in vivo*.

**Methods:** Two participants with HIV viremia (plasma HIV RNA \>1,000 copies/mL) and seven on suppressive ART (\<40 copies/mL) underwent bronchoscopy. Bronchoalveolar lavage (BAL) was separated into cellular and cell-free fractions by centrifugation. AM were purified from BAL cells by plastic adherence. Plasma and peripheral blood cells (PBMC) were collected. HIV RNA in the plasma and BAL supernatant, as well as cell-associated HIV DNA and RNA (CAD, CAR) in AM, total BAL cells and PBMCs were assayed by qPCR targeting *pol*. To detect contaminating or ingested CD4+ T cells, T-cell receptor (TCR) RNA was tested by PCR.

**Results:** Most participants (89%) were male. Median age was 50 yrs and CD4 count was 735. Donors on ART were suppressed for median of 3.6 yrs (range 2.4--12.3). In viremic participants, CAD and CAR were detected in AM (median 1.5 and 2.5 log~10~ copies/10^6^ cells) and in PBMC (2.4 and 1.5). HIV RNA in BAL supernatant was low compared to plasma (median 0.9 and 4.4 log~10~ copies/mL). CAD was detected in AM from 6 of 7 participants on ART (median 1.7 log~10~ copies/10^6^ cells) and CAR from 4 of 6 with detectable CAD (1.3). AM extracts were negative for TCR in 5 of 6 participants with samples available. By comparison, CAD was detected in PBMC from 6 of 6 individuals tested (median 2.5 log~10~ copies/10^6^ cells) and CAR in 2 of 6 (1.9). HIV RNA in BAL supernatant was not detectable (\<0.3 copies/mL) despite low-level plasma HIV RNA in 6 of 7 suppressed participants (median 7.7 copies/mL).

**Conclusions:** These results establish the persistence of HIV-infected alveolar macrophages in individuals on suppressive ART, which cannot be explained by contaminating or ingested CD4+T-cells. Studies are ongoing to characterize the proviruses in alveolar macrophages and their inducibility.
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OP 5.0

Immune control of HIV reservoirs and cure therapeutic strategies

B. Autran

Pitié Salpêtrière Hospital, Paris, France

Abstract not available at the time of printing
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OP 5.1

Long-term spontaneous control of HIV-1 relates to low frequency of infected cells and inefficient viral reactivation

J.G. Prado^5^\*, N. Noel^1--4^, R. Peña^5^, A. David^6^, V. Avettand-Fenoel^7,8^, I. Erkizia^5^, E. Jimenez^5^, C. Lecuroux^1,3^, C. Rouzioux^7,8^, F. Boufassa^9^, G. Pancino^10^, A. Venet^1^, C. Van Lint^11^, J. Martinez-Picado^5,12,13^, O. Lambotte^1--4^, A. Sáez-Cirión^6^\* and for the ANRS CO21 Cohort

*^1^Université Paris Sud , UMR-1184, France, ^2^CEA, DSV/iMETI, Division of Immuno-Virology, IDMIT, France, ^3^Inserm, U1184, Center for immunology of viral infections and autoimmune diseases, France, ^4^APHP, Service de Médecine Interne & Immunologie Clinique, Hôpitaux Universitaires Paris Sud, le Kremlin Bicêtre, France, ^5^AIDS Research Institute -IrsiCaixa-, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain,, ^6^Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France, ^7^APHP, Hôpital Necker, Service de Virologie, Paris, France, ^8^Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, EA7327, Paris, France, ^9^INSERM U1018, Faculté de Médecine Paris Sud, Le Kremlin-Bicêtre, France, ^10^Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France, ^11^Service de Virologie Moléculaire, IBMM, Université Libre de Bruxelles (ULB), Gosselies, Belgique, ^12^Universitat de Vic, Barcelona, Spain, ^13^Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain* \*equal contributors

**Background:** HIV-1 establishes reservoirs of infected cells that persist despite effective antiretroviral therapy (ART). A low frequency of HIV-1 infected cells has been associated with delayed viral rebound after ART interruption. Individuals who control HIV-1, the HIV-1 controllers (HICs) carry particularly low levels of infected cells. Here, we evaluate the role of the low number of HIV-1- infected cells in HICs to long-term spontaneous viral control.

**Methods:** We analysed 38 HICs and 12 patients on ART. We measured HIV-1 reactivation from resting CD4+ in the presence of: PHA/IL-2, anti-CD2/CD28, IL-7, prostatin, HMBA, 5-AzadC, chaetocin and SAHA and quantified HIV-1 RNA in the supernatants. We evaluated HIV-1 production in co-cultures of CD4+ with PBMC from seronegative donors and monitored viral outgrowth by p24 ELISA. We tested viral spread in those supernatants with p24\>10 pg/mL. HIV-1 proviral DNA was quantified in resting CD4+ and total PBMCs. We evaluated CD8+ function in HICs by measuring CD8+ suppressive capacity against HIV-1 and IFN-γ production in response to optimal HIV-1 peptides.

**Results:** We found a lower number of HIV-1 reactivating conditions in HICs (4 HICs *vs.* 10 ARTs; *P*=0.01) that directly correlated with the proviral DNA levels in the resting CD4+ subset (Spearman 0.88; *P*\<0.0001). Our data revealed a diminished HIV-1 production (9 HIC *vs.* 35 pg/mL ART, *P*=0.041) and lower frequency of spreading infections (3% HIC *vs.* 21.4% ART; *P*=0.045) in HICs. Viral production from CD4+ directly correlated to proviral DNA levels in PBMCs. Potent CD8+ responses with higher suppressive capacity and IFN-γ production were present in HICs whose CD4+ T cells produced virus.

**Conclusions:** Long-term spontaneous control of HIV-1 in HICs is sustained on the inefficient reactivation of viruses from a limited number of infected cells and the capacity of HICs to activate potent HIV-specific CD8+ responses to counteract viral reactivation events.
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OP 5.2

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure

G. Clutton, N. Archin, Y. Xu, D.M. Margolis, N. Goonetilleke

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**Background:** A number of drugs have been demonstrated to induce HIV RNA production from latently-infected cells. It is hoped that one or more of these latency-reversing agents (LRAs) will be combined with a vaccine capable of eliciting cytotoxic T cells to clear reactivated cells. Therefore, we studied the effects of these drugs on T cells.

**Methods:** We examined the *in vitro* impact of clinically-relevant exposures to putative LRAs on T cell activation and function. Histone deacetylase inhibitors (HDACi) vorinostat (VOR), panobinostat (PAN) and romidepsin (ROMI) were compared with protein kinase C modulators ingenol 3,20 dibenzoate (ING), prostratin (PRO) and bryostatin-1 (BRYO).

**Results:** No effect of VOR was observed on T cell activation, whereas PAN and ROMI consistently increased expression of CD69 on CD4 and CD8 T cells. PKC modulators all induced increased expression of CD69 and MHC I on CD4 and CD8 T cells, which for CD69 was sustained over 72 hours. VOR and ROMI did not impact *ex vivo* antigen-specific CD8 T cell responses as measured by degranulation and cytokine production six hours after stimulation. PAN, however, produced a small but significant decrease in the frequency of antigen-specific CD8 T cell responses. PKC modulators all induced non-specific cytokine production, an effect that was more marked in HIV seropositive than in seronegative individuals, but did not significantly affect antigen-specific responses. Interestingly, ROM, PRO and BRYO inhibited antigen-dependent proliferation over a 5 day *in vitro* culture in both seropositive and seronegative participants. PRO and BRYO were toxic in these short term culture assays.

**Conclusions:** Even within the same class, LRAs vary in their effect on the phenotypic profile and functional capacity of T cells. Moreover, effects on T cell function may not be detectable until several days after dosing. These differences should be considered for dosing, designing and testing of HIV latency clearance strategies.
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OP 5.3

CD8+ sensing relies on nanomolar levels of antigen presented upon HIV-1 reactivation

A. Ruiz^1^, E. Jimenez^1^, R. Peña^1^, P. Goulder^2^, B. Clotet^1^, J.G. Prado^1^

^1^AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ^2^Department of Pediatrics, University of Oxford, UK

**Background:** Latency-reversing agents (LRAs) have being developed as strategy to reactivate silent provirus and eliminate HIV-1 reservoirs. However, the lack of cytopathic effects associated with LRA treatment precludes the elimination of reactivated cells and immune recognition is needed. The level of viral protein expression induced by LRAs upon reactivation for CD8 T-cell sensing is unknown, but it is key for recognition and killing of reactivated cells. Here, we aimed to define the level of HIV-1 reactivation needed for CD8 T-cell recognition.

**Methods:** We generated a resting-like latency model by infecting U937 cells with HIV-1GFP and culturing four days the GFP-negative cells with PIs. Resting-like cells were reactivated for 48 hours with PMA+ionomycin (PMA/IO) at different doses, panobinostat (PNB) at 30 nM or PNB+bryostatin at 10 nM. HIV-1 specific CD8 T-cells were added 20 hours after reactivation. We measured HIV-1 reactivation by intracellular p24 and CD8 T-cell activity by MIP1β/CD107a and IFN-γ staining. For comparison, we quantified CD8 T-cell activity in the presence of U937 cells pulsed with dilutions of cognate peptide.

**Results:** Our model produced a 2-fold with PMA/IO, a 1,3-fold with PNB and a 1,6-fold HIV-1 induction with PNB+bryostatin, compared to controls. Associated toxicity was low and did not affect CD8+ T-cells. Despite low levels of HIV-1 induction, we measured a specific increased in CD8+ T-cell activity after reactivation ranging from 4 to 7,2 % in MIP1β/CD107a expression and 2,6% to 7,4% in IFN-γ expression. By extrapolation of the data into a peptide-pulse standard curve, the threshold for CD8 T-cell activation in response to HIV-1 reactivation was 10^3^ nM.

**Conclusions:** CD8 T-cell sensing is limited by a nanomolar threshold of antigen presented in the surface of reactivated cells. Our model could be a useful tool for screening of novel LRAs able to reactivate latently HIV-1 infected cells and to induce CD8+ T-cell recognition.
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OP 5.4

Long-lived Th17 subsets contribute to HIV-1 persistence under ART

P. Ancuta^1,2^\*, V.S. Wacleche^1,2^, J.P. Goulet^3^, A. Gosselin^2^, P. Monteiro^1,2^, H. Soudeyns^1,4^, M.A. Jenabian^5^, S.G. Deeks^6^, N. Chomont^1,2^, J.P. Routy^7,8^

^1^Université de Montréal, Faculté de Médecine, Département of microbiologie, infectiologie et immunologie, Montreal, QC, Canada, ^2^Centre de recherche du CHUM, Montreal, QC, Canada, ^3^Caprion, Montreal, QC, Canada, ^4^Unité d'immunopathologie virale, Centre de recherche du CHU Sainte-Justine, Montreal, QC, Canada, ^5^Département des sciences biologiques, Université du Québec, Montreal, QC, Canada, ^6^Department of Medicine, University of California San Francisco, San Francisco, CA, USA, ^7^Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Montreal, QC, Canada, ^8^Division of Hematology, McGill University Health Centre, Montreal, QC, Canada

The current paradigm is that Th17 cells are permissive to HIV-1 infection and subsequently depleted. Indeed, subsets of memory CD4+ T-cells with CCR6+CCR4+ (Th17 enriched) and CCR6+CXCR3+ (Th1Th17 enriched) phenotypes are HIV permissive and their frequency is not restored by ART. Whether fractions of Th17 cells are long-lived in humans and contribute to viral persistence under ART remains unknown. Here, we performed an in-depth transcriptional and functional characterization of two novel CCR6+ subsets, lacking (double negative, CCR6+DN) or co-expressing CXCR3 and CCR4 (double positive, CCR6+DP) and investigated their contribution to HIV persistence in ART-treated subjects. CCR6+DN and CCR6+DP shared with CXCR3+CCR6+/Th1Th17 and CCR4+CCR6+/Th17 multiple Th17-polarization markers and *C. albicans* antigenic specificity. All four subsets exhibited lineage commitment and plasticity when cultured under Th17 and Th1 conditions, respectively. In contrast to CCR6+DP and CXCR3+CCR6+/Th1Th17, fractions of CCR6+DN and CCR4+CCR6+/Th17 maintained their Th17-effector functions under Th1-polarization conditions, suggesting their stable Th17-lineage commitment. Despite these similarities, CCR6+DN expressed a unique transcriptional signature indicative of early Th17 development, lymph-node homing, follicular help, and self-renewal. Although all four CCR6+ subsets carried replication-competent integrated HIV-DNA, CCR6+DN distinguished from the other three subsets by preserved frequency/counts in ART-treated HIV-infected subjects versus uninfected controls. Longitudinal studies demonstrated that CCR6+DN cells were the most predominant CCR6+ subset in the blood before and after ART initiation. Finally, CCR6+DN were enriched within the memory CCR6+ fraction in lymph nodes versus blood. Together these results demonstrate the existence of at least four distinct stages of Th17 differentiation in humans and support the contribution of long-lived CCR6+DN cells to HIV-DNA persistence under ART.
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Uncovering mechanisms of HIV persistence in HIV controllers by HIV sequence analysis in CD4 T cell subsets

E. Boritz, S. Darko, F. Simonetti, D. Wells, X. Wu, L. Swaszek, G. Wolf, R. Hoh, A. Vostal, A. Ober, M. Hughes, D. Bunis, S. Migueles, J. Casazza, R. Koup, M. Connors, S. Moir, J. Martin, F. Maldarelli, S. Hughes, S. Deeks, D. Douek

Vaccine Research Center, NIAID, Bethesda, MD, USA

A small number of HIV-infected adults control HIV without antiretroviral therapy (ART). Characterizing how HIV persists in these individuals may elucidate barriers to HIV cure. We studied 14 HIV controllers (defined by plasma HIV-1 RNA\<10^3^ copies/mL off ART) as well as 6 non-controllers with higher virus loads. CD4 T cell subsets were sorted by FACS. Clonal HIV env sequence fragments were derived from cellular DNA or virion cDNA and used for phylogenetic analysis. T cell receptor beta chain genes and HIV integration sites were determined by deep sequencing. We found that whereas the peripheral blood CD4 T cell pool in non-controllers harbored diverse HIV strains, blood CD4 T cells in HIV controllers harbored large clusters of identical sequences that were distinct from plasma viruses, suggesting clonal expansion of HIV-infected cells. Diversity of both HIV DNA sequences and T cell receptor beta chain genes in controllers was lower in effector memory (EM) than in central memory (CM) or transitional memory (TM) cells, suggesting an accumulation of clonally expanded HIV proviruses in the EM population. Integration site sequencing confirmed clonal expansion of HIV-infected cells in controllers. Some cells from some expanded, HIV-infected CD4 T cell clones in HIV controllers produced virions when stimulated *in vitro*. Unlike CD4 T cells in blood, lymph node (LN) CD4 T cells in HIV controllers harbored diverse virus strains closely related to plasma viruses. Among LN CD4 T cell subsets, T follicular helper cells most often harbored HIV DNA, but other subsets were also infected. We conclude that the predominant HIV reservoir in blood from HIV controllers is an oligoclonal population of expanded T cells, some of which may produce virus upon restimulation. By contrast, the lymphoid tissue in HIV controllers harbors diverse HIV strains that appear to be actively replicating. Both HIV populations may be barriers to cure, even in persons with potent antiviral defenses.
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The transcriptional program governed by RORγt favors HIV-1 replication in CCR4+CCR6+ Th17 cells

V. S. Wacleche^1,2^, A. Cleret-Buhot^1,2^, Y. Zhang^1,2^, D. Planas^1,2^, J.P. Goulet^3^, P. Monteiro^1,2^, J. Niessl^1,2^, A. Gosselin^2^, C. Tremblay^1,2^, M.A. Jenabian^4^, J.P. Routy^5,6,7^, M. El-Far^2^, N. Chomont^1,2^, E.K. Haddad^8^, R.P. Sekaly^9^, P. Ancuta^1,2^

^1^Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université de Montréal, QC, Canada, ^2^CHUM-Research Centre, Montréal, QC, Canada, ^3^Caprion, Montréal, QC, Canada, ^4^Département des sciences biologiques, Université du Québec, Montreal, QC, Canada, ^5^Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada, ^6^Research Institute, McGill University Health Centre, Montreal, QC, Canada, ^7^Division of Hematology, McGill University Health Centre, Montreal, QC, Canada, ^8^Drexel University, Division of infectious Diseases and HIV Medicine, Philadelphia, PA, USA, ^9^Case Western Reserve University, Center for AIDS Research, Cleveland, OH, USA

HIV-1 infection is characterized by profound CD4+ T-cell destruction, with a marked Th17 dysfunction at mucosal level that is not restored in chronically infected subjects receiving antiretroviral therapy. In an effort to orient Th17-targeted reconstitution strategies, herein we investigated molecular mechanisms of HIV permissiveness in Th17 cells. Genome-wide transcriptional profiling in memory CD4+ T-cell subsets enriched in cells exhibiting Th17 (CCR4+CCR6+), Th1 (CXCR3+CCR6-), Th2 (CCR4+CCR6-), and Th1Th17 (CXCR3+CCR6+) features revealed the most remarkable transcriptional differences between Th17 and Th1 subsets. Accordingly, HIV-DNA integration was superior in Th17 versus Th1 upon exposure to both wild-type and VSV-G-pseudotyped HIV, indicative that post-entry mechanisms contribute to enhanced viral replication. Unique pathways enriched in Th17 versus Th1 included TCR signaling, T-helper differentiation, nuclear receptor transcription, and circadian repression of expression by REV-ERBα. Transcripts significantly enriched in Th17 versus Th1 were previously associated with the regulation of TCR signaling (ZAP-70, Lck, CD96), Th17 polarization (RORγt, ARNTL, PTPN13, RUNX1), and HIV replication (PPARG, PAK2, KLF2, ITGB7, PTEN, ATG16L1, Alix/AIP1/PDCD6IP, LGALS3, JAK1, TRIM8, MALT1, FOXO3, ARNTL/BMAL1, ABCB1/MDR1, TNFSF13B/BAFF, CDKN1B). Functional studies demonstrated increased Lck and ZAP-70 phosphorylation, proliferation potential, and NF-κB nuclear translocation and DNA-binding activity in Th17 versus Th1. Finally, RNA interference studies identified the Th17-specific transcription factor RORγt as a novel HIV dependency factor. Thus, the transcriptional program governed by RORγt includes molecules that regulate HIV replication at multiple post-entry steps, molecules that may represent potential targets for novel therapies aimed at protecting Th17 cells from infection and subsequent depletion.
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Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells

J. Boucau, J. Madouasse, D. Wambua, M.J. Berberich, S. Le Gall

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

**Background:** Strategies to purge HIV reservoirs commonly rely on reactivation of HIV provirus by latency-reversing agents (LRA) followed by death or immune clearance of reactivated CD4 T cells. LRAs such as HDAC inhibitors or PKC agonists showed variable efficacy *in vitro* and limited efficacy in clinical trials. While productive infection mostly occurs in activated CD4 T cells, reactivation occurs in memory resting cells receiving LRA and ART. How these parameters shape HIV antigen processing and presentation by CD4 T cells is unknown despite its critical role in immune recognition after reactivation.

**Methods:** We measured hydrolytic activities of cellular proteases involved in antigen processing in live primary CD4 T cells that were either resting, CD3/28-activated, LRA-treated, or in conditions used in the Lewin or Planelles latency models. To assess how changes in activities affect antigen processing we compared the degradation of HIV peptides in extracts of primary CD4 T cells treated as stated above. The degradation products were quantified by mass spectrometry and their antigenicity measured by killing assay with HIV-specific CTL.

**Results:** The peptidase activities of HDACi-treated primary CD4 T cells decreased by 20--60% compared to resting cells while PKCa-treated cells displayed enhanced activities comparable to activated cells. Memory-like CD4 T cells of the Lewin latency model showed activities level similar to resting CD4 T cells. CD4 T cells of the Planelles model displayed activities similar to activated cells. *In vitro* degradation of HIV epitope-containing peptides showed that resting primary CD4 T cells produced longer, more antigenic peptides and unique cleavage sites compared to activated cells, and that some LRAs caused discrete changes in degradation patterns.

**Conclusions:** These variations in peptidase activities and degradation patterns suggest that LRA-reactivated and productively infected CD4 T cells might process antigen differently, thus requiring different CTL responses for effective clearance.

Session 6: Pharmacology of HIV persistence {#jve13-sec-0035}
==========================================

 {#jve13-sec-1006}

OP 6.0

A pharmacologic basis for HIV persistence

C. Fletcher

University of Nebraska Medical Center, Omaha, NE, USA

Abstract not available at the time of printing
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OP 6.1

A subset of infectious proviruses persist and expand following activation *ex vivo*

J.K. Bui^1,2^, E. Halvas^1^, E. Fyne^1^, M.D. Sobolewski^1^, D. Koontz^1^, M.F. Kearney^3^, W. Shao^4^, F.F. Hong^1^, J.W. Mellors^1^

^1^University of Pittsburgh, Department of Medicine, Pittsburgh, PA, USA, ^2^Howard Hughes Medical Institute, Medical Research Fellows Program, Bethesda, MD, USA, ^3^National Cancer Institute (NCI), HIV Dynamics and Replication Program, Frederick, MD, USA, ^4^Leidos, Advanced Biomedical Computing Center, Frederick, MD, USA

**Background:** The most effective latency-reversing agents for HIV-1 are also potent T-cell activators. Recent studies show that virus-producing cells can persist and expand *in vivo*. We hypothesized that activation of HIV-infected CD4+ T-cells could lead to clonal expansion of proviruses rather than their elimination.

**Methods:** We established an *ex vivo* cell culture system involving stimulation of patient-derived CD4+ T cells with PMA/ionomycin (day 1--7), followed by rest (day 7--21), and then restimulation (day 21--28) in the presence of raltegravir and efavirenz. Cell-associated HIV-1 DNA (CAD) and virion RNA in the supernatant were quantified by qPCR. Single-genome sequencing (SGS) was performed to characterize proviruses and virion RNA. The replication-competence of proviruses in cultured cells was determined by the viral outgrowth assay (VOA) at multiple time points.

**Results:** Experiments were performed with purified CD4+ T-cells from five consecutive donors who had been suppressed on ART for ≥ 2 years (median = 13.4 years). In all experiments, HIV-1 RNA levels in supernatant increased following initial stimulation, decreased or remained stable during the rest period, and increased again with restimulation. Cell-associated HIV-1 DNA levels did not show a consistent pattern of change. SGS revealed outcomes of proviral populations including both elimination and expansion. Importantly, a subset of proviruses expanded and produced infectious virus continuously.

**Conclusions:** Reversal of HIV-1 latency by CD4+ T cell activation results in diverse outcomes for proviral populations, ranging from their apparent elimination to expansion of proviruses capable of infectious virus production. These findings underscore the complexity of eliminating HIV reservoirs with latency-reversal agents and highlight the need for new strategies to kill HIV-infected cells before they can clonally expand.
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OP 6.2

Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?

A. Gramatica, W.C. Greene, M. Montano

Gladstone Institute of Virology and Immunology and the University of California, San Francisco, CA, USA

**Background:** HIV latency is established early during acute infection and is primarily found within memory CD4 T cells residing in lymphoid tissue. However, due to their ease of acquisition, blood CD4 T cells are almost exclusively studied in latency-reversing experiments. Here, we compared CD4 T cells from blood and lymphoid tissue for their responses to various latency-reversing agents (LRAs).

**Methods:** A primary CD4 T-cell model of latency involving spinoculation of an infectious clone of NL4-3 expressing firefly luciferase from the native LTR was used to examine the responses of latently infected blood and tonsil cells to various LRAs. Luciferase activity was quantitated to assess reactivation of latent provirus.

**Results:** In our preliminary results, latently infected cells from lymphoid tissue displayed a more robust response than blood to several LRAs. CD4 T cells from lymphoid tissue had a slightly higher state of cellular activation as evidenced by increased expression of HLA-DR and CD69. In contrast, levels of CD25 were not higher. Tonsil cells displayed far greater responses to single agents, (e.g. ingenol B, JQ1 and HDACi). These responses were often observed within 24 hours of stimulation and often exceeded the response elicited by anti-CD3/CD28 antibodies. Synergistic activation was frequently observed when ingenol B was combined with HDACi or JQ1. In contrast, blood CD4 T cells responded only weakly to single agents. While combinations of ingenol B and HDACi or JQ1 modestly synergized, the responses were consistently weaker than the response elicited by anti-CD3/CD28 antibodies.

**Conclusions:** Lymphoid tissue CD4 T cells responded more strongly to a variety of single LRAs and displayed marked synergy when combinations of agents were used. These findings suggest that latency reversal may be more easily achieved in lymphoid tissues than in blood. Since the reservoir principally resides in lymphoid tissue, increased testing of such tissues should be encouraged.
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Role of drug transporters and metabolic enzymes in antiretroviral drug (ARV) disposition in testicular tissue: potential contribution to HIV-1 persistence

R. Bendayan, Y. Huang, S.K. Whyte, T. Hoque, M.A. Jenabian, K. Vyboh, N. Sheehan, P. Brassard, M. Belanger, N. Chomont, C.V. Fletcher, J.P. Routy

University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, USA

**Background:** Human immunodeficiency virus (HIV-1) is capable of persistent infection in the testis, where inadequate ARV penetration could be due in part to the functional expression of drug efflux transporters at the blood--testis barrier (BTB). This study aims to characterize expression and localization of drug transporters and metabolic enzymes in human testes and quantify ARV concentrations in HIV-infected testicular tissue. Since nuclear receptors can induce functional expression of drug transporters and metabolic enzymes in various tissues, we investigated the regulation of efflux transporters by these receptors.

**Methods:** mRNA and protein expression of the ATP-binding cassette (ABC) and solute carrier (SLC) transporters, phase I metabolic enzymes, and nuclear receptors were evaluated in testicular tissue obtained from uninfected (*n*=8) and HIV-1 infected (*n*=5) subjects on ARV therapy. Localization of transporters and metabolic enzymes was determined by confocal microscopy. ARV concentrations in testicular tissue or plasma were quantified by LCMS/MS. Nuclear receptor expression and their effect on efflux transporters following activation by ligands were investigated in TM4 Sertoli cells representing mice BTB.

**Results:** Expression and localization of ABC (P-gp, BCRP, MRPs) and SLC (OATP, OAT, OCT, CNT, ENT) transporters, as well as CYP3A4 and CYP2D6 were confirmed in human testes. HIV-protease inhibitors that are known substrates for ABC transporters displayed low testicular tissue penetration. Nuclear receptors, PXR, CAR, PPARs, were also expressed in human testicular tissue and TM4 Sertoli cells and mediated induction of P-gp and BCRP.

**Conclusion:** Our findings suggest that drug transporters, metabolic enzymes and nuclear receptors involved in ARV disposition are present in the testes, and could limit ARV tissue penetration; this could potentially contribute to persistent HIV-1 infection and formation of a viral sanctuary site. (Supported by CIHR).
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Approaches to discover latency-reversing agents
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OP 7.2

Gene editing CCR5 in HIV subjects CD4 T cells

D. Ando

CMO Sangamo BioSciences, Richmond, VA, USA

**Background:** CCR5 modified autologous CD4 cells (SB-728-T) are safe and increase total CD4 counts. The cells traffic to lymphoid tissues and have a selective survival advantage during ART treatment interruption (TI). Additional studies in CCR5 Δ32 heterozygote HIV subjects showed VL reductions during TI correlated with circulating bi-allelic CCR5-modified CD4 cells supporting the importance of maximizing engraftment. Studies in immunologic non-responders show an increase of CD4 counts to \>500 cells/μL and a 0.9 log decrease in proviral DNA measured in PBMC.

Low dose CTX has been successfully used to increase T cell engraftment. This study examines the effect of escalating doses of CTX on SB-728-T engraftment.

**Methods:** A dose escalation study of IV CTX, with doses ranging from 100 mg/m^2^ to 2 g/m^2^ (*n*=3--6/cohort), administered 1--3 days prior to SB-728-T (\>90% CD4, \<1% CD8) infusion was performed in 18 aviremic, ART treated HIV subjects with CD4 T cells ≥500/μL.

**Results:** CTX was generally well tolerated with low grade GI side-effects, managed with anti-emetics at doses up to 1 g/m^2^. Grade 3 and 4 neutropenia requiring G-CSF developed at 1.5 and 2.0 g/m^2^ CTX. On day 7, a dose-related increase in CD4 count and engraftment of bi-allelic CCR5 modified cells was observed with CTX doses up to 1 g/m^2^ but did not increase at 2.0 and 1.5 g/m^2^. By comparison, there was a progressive decline in CD8 cells with CTX dose escalation. Data is expressed as mean±SE.

A 1-log VL reduction from peak was seen in one subject each at 100 and 500 mg/m^2^ of CTX while one subject each at the 1 and 1.5 g/m^2^ dose level had a 2-log decline during a TI. At the conclusion of the study, three additional subjects were conditioned with 1 g/m^2^ of CTX and administered CCR5 modified T cells containing 46.9±6.4% CD8 cells. CD8 count increased by 2236±967/μL (range 1029--4150/μL) with only modest increases in CD4 counts (733±233/μL; range 297--1096/μL) at 7 days in the three subjects. Two of the three subjects have had VL decreases to date during TI (\<1000 copies/mL), suggesting an effect on viral control with the added CD8 T cells.

**Conclusion:** CTX conditioning is generally well tolerated and was associated with increased engraftment of CCR5-modified T cells at doses up to 1 g/m^2^ in HIV subjects. CTX conditioning may be a useful strategy to maximize the engraftment and anti-viral effects of SB-728-T. The effects of co-administering CD8 cells with SB-728-T on VL will be presented.
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Cyanotriazoles activate latent HIV and strongly synergize with proteasome inhibitors *ex vivo* in resting CD4 T cells from suppressed HIV+ donors

J. Murry^1^, A. Tsai^1^, M. Graupe^1^, G. Jones^1^, M. Tsiang^1^, A. Arvey^1^, L. Li^1^, G. Stepan^1^, H. Yu^1^, T. Cihlar^1^, D. Sloan^1^, J. Lalezari^2^

^1^Gilead Sciences, Foster City, USA, ^2^Quest Clinical Research, San Francisco, CA, USA

**Background:** Current HIV therapies do not cure HIV because latent reservoirs persistent within infected CD4+ T cells. The induction of viral proteins in latently infected cells could facilitate their recognition and elimination by immune cells.

**Methods:** High throughput screening was used to identify novel compounds that induce viral expression in primary CD4 T cells infected *in vitro* with an HIV reporter virus. Active compounds were tested *ex vivo* for the induction of cell-associated HIV RNA transcripts and supernatant virions in resting CD4 T cells isolated from cART-suppressed HIV infected donors.

**Results:** We identified cyanotriazole-containing compounds that activate latent HIV. The most active hit, GS-46, induced 3.1-fold activation of virion production *ex vivo*, similar to the 3.6-fold activation induced by romidepsin (geometric mean, *n*=10). However, unlike HDAC inhibitors, GS-46 increased the production of polyadenylated HIV transcripts without affecting readthrough transcripts. The structure-activity relationship indicates that the cyanotriazole is required for activity, suggesting potential covalent modification of the target(s). Pairwise LRA combinations were tested and the most synergistic was the combination of cyanotriazoles with proteasome inhibitors (PIs), such as bortezomib. While a 24 hour pulse of 15 nM bortezomib alone induced 1.4-fold activation of HIV *ex vivo*, 40-fold activation was observed in combination with 3 uM GS-46 (geometric means, *n*=10). By comparison, PMA and ionomycin induced 63-fold induction. However, unlike mitogenic activation, the combination of GS-46 with bortezomib had minimal effects on cellular proliferation, T cell activation marker expression, or cytokine production.

**Conclusions:** Cyanotriazole-containing small molecules have been identified as a new class of LRAs. Cyanotriazoles strongly synergize with PIs to induce HIV latency reversal at levels similar to those seen with mitogenic stimulus, but without T cell activation.
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Triazol-1-ol analogues as novel therapeutic leads towards reactivating and eradicating latent HIV-1 by manipulating SUMOylation of STAT5

A. Bosque^1^, A. Macedo^1^, A. Spivak^2^, C.L. Novis^1^, L.J. Martins^1^, M. Szaniawski^1^, N.M. Archin^3^, P.A. Luciw^4^, D.M. Margolis^3^, V. Planelles^1^

^1^Department of Pathology, University of Utah, Salt Lake City, UT 84132, USA, ^2^Department of Medicine, University of Utah, Salt Lake City, UT 84132, USA, ^3^Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA, ^4^Department of Pathology and Laboratory Medicine, School of Medicine, University of California at Davis, Davis, CA 95616, USA

**Background:** Reactivation of latent HIV *in vivo* for the purpose of purging the viral reservoir represents a formidable challenge. One major problem is to identify stimuli that will effectively reactivate latent proviruses without causing overt T-cell activation or proliferation. We have performed a medium-throughput screen of chemical libraries and have identified a family of compounds (triazol-1-ol analogues) that trigger viral reactivation.

**Methods:** We have characterized the ability of several triazol-1-ol analogues to i) reactivate latent virus; ii) reduce the pool of latently infected cells *in vitro*; iii) hamper the establishment of latency; iv) induce cell proliferation, activation and cytokine release in resting CD4 T cells; and finally v) we have characterized the mechanism of action of triazol-1-ol analogues involved in viral reactivation. To that end, we have used a primary cell model of HIV-1 latency that recapitulates the generation of latently infected cultured T~CM~ and uses a replication competent virus and ART.

**Results:** We have found that triazol-1-ol analogues reactivate latent HIV-1 in cultured T~CM~ in a dose dependent manner and in the absence of T cell proliferation, activation or cytokine release. Importantly, viral reactivation is followed by cell death of the reactivated cells and decreased in the pool of latently infected cells *in vitro*. Furthermore, these compounds also have the ability to hamper the establishment of latency in cultured T~CM~. Analysis of the mechanism of action indicates that activation of latent HIV by triazol-1-ol analogues involves inhibition of SUMOylation of STAT5, a mechanism involved in downregulation of STAT5 activity.

**Conclusions:** These results demonstrate that triazol-1-ol analogues can be utilized to trigger activation of latent proviruses in primary cells. Key signaling elements controlling this pathway should be considered as novel therapeutic targets toward eradication.
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Challenges in designing clinical trials in cure research
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Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV

A.L. Hill^1^, D.I.S. Rosenbloom^2^, D.R. Kuritzkes^3^, R.F. Siliciano^4^, T.J. Henrich^5^

***^1^****Program for Evolutionary Dynamics, Harvard University, Cambridge, MA, USA, ^2^Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA, ^3^Division of Infectious Diseases, Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA, USA, ^4^Department of Medicine, Johns Hopkins University School of Medicine and Howard Hughes Medical Institute, Baltimore, MD, USA, ^5^Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA, USA*

**Background:** Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The limited ability to sample and quantify latent infection means that supervised antiretroviral therapy (ART) interruption studies are generally required.

**Methods:** We introduce a set of mathematical and statistical modeling tools to aid in the design and interpretation of ART-interruption trials. These tools combine previously developed models of reservoir dynamics and rebound with patient-derived data in a flexible Bayesian framework.

**Results:** We show how the likely size of the remaining reservoir can be updated in real-time as patients continue off treatment, by combining the output of laboratory assays with insights from dynamic models. We design an optimal schedule for viral load sampling during interruption, whereby the frequency of follow-up can be decreased as patients continue off ART without rebound. While this scheme can minimize costs when the chance of rebound between visits is low, we find that the reservoir will be almost completely reseeded before rebound is detected unless sampling occurs at least every two weeks and the most sensitive viral load assays are used. We use simulated data to predict the clinical trial size needed to estimate treatment effects in the face of highly variable patient outcomes and imperfect reservoir assays. Our findings suggest that large numbers of patients -- between 40 and 150 -- will be necessary to reliably estimate the reservoir-reducing potential of a new therapy and to compare this across interventions. As an example, we apply these methods to the two "Boston patients".

**Conclusions:** These tools can aid researchers in evaluating new potentially-curative strategies that target the latent reservoir.
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The importance of GPP implementation in HIV cure research: learning from prevention

J. Handibode, S. Hannah

AVAC, New York, NY, USA

**Background:** HIV prevention research has experienced community resistance to and strong community support for conduct of trials to advance the field. Where there is resistance, , delays in research timelines, and early closures have occurred. Recently, there has been an increase in HIV cure research, specifically safety and phase I/II clinical trials. As this research increases, so will the need for stakeholder engagement. The UNAIDS/AVAC Good Participatory Practice guidelines for biomedical HIV prevention trials (GPP) serve as a global reference for stakeholder engagement throughout the trial lifecycle. Adoption of GPP fosters ethical trial conduct and eases the trial process through early and broad stakeholder support. GPP has been implemented in a variety of ways for HIV prevention research. Lessons learned can serve as a framework for engagement in cure research moving forward.

**Methods**/**Results:** In South Africa, AVAC has conducted GPP trainings with several major HIV research institutions including Desmond Tutu HIV Foundation, Wits Reproductive Health and HIV Institute, and CAPRISA. In 2012 the FACTS 001 team used various GPP tools and strategies, including monitoring and evaluation tools and the GPP Blueprint, to standardize engagement at all sites. Recently South Africa has begun the process of developing a country-wide framework for stakeholder engagement rooted in GPP. This framework will be developed by community engagement managers at provincial levels who then coordinate with national stakeholders to achieve national adoption.

In Thailand, GPP has been rolled out with leading research organizations and is a key focus of the National Biomedical HIV Prevention Subcommittee of the Ministry of Public Health. Thailand has also formed a National CAB to provide civil society an independent platform to weigh in on the conduct of clinical trials in the country.

AVAC has organized a community of practice to gather and analyze best practices related to stakeholder engagement. These models and practices of GPP implementation may be used, replicated, or adapted for cure research.

**Conclusion:** Uptake and implementation of GPP within current and future HIV cure trials and programs will help site and trial leadership better establish and adjust community engagement goals that strategically align and complement the scientific research agenda.
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Emerging results of an extensive survey of potential participants' willingness to take risks in and donate to HIV cure research in the United States

J. Taylor^1^, K. Dubé^1,4^, D. Evans^2^, L. Sylla^3^, A. Burton^1^, A. Skinner^4^, S. Greene^4^

^1^Collaboratory of AIDS Researchers for Eradication (CARE) Community Advisory Board (CAB), USA, ^2^Delaney AIDS Research Enterprise (DARE) CAB, USA, ^3^DefeatHIV CAB, USA, ^4^Health Policy and Management, University of North Carolina at Chapel Hill, NC, USA

**Background:** We assessed willingness to take risks and donate blood and tissues in HIV cure-related studies among adults living with HIV in the United States. We focused on attitudes toward perceived personal and societal risks and benefits of participation.

**Methods:** An extensive, online cross-sectional survey was conducted among 302 American adults (76.4% males; 22.2% females; 0.7% male-to-female transgenders) aged ≥ 18 years between September and October 2015. The sample was ethnically diverse (64.8% Caucasian, 16.6% African-American, 12.0% Hispanic, 1.3% Asian, 2.6% mixed) and 38 U.S. states were represented. Data collection and analyses are ongoing.

**Results:** Almost all respondents -- 99.0% (95% CI: 97.9--100.0%) -- were currently taking HIV medications and 96.3% (95% CI: 94.2--98.4%) were generally interested in HIV cure research. Eight percent reported participation in at least one clinical HIV cure-related study. Research types that respondents would most likely be willing to participate in were those that included: 1) blood draws (92.9%; 95% CI: 89.9--95.9%); 2) leukaphereses (74.3%; 95% CI: 69.3--79.3%); 3) therapeutic vaccinations (76.9%; 95% CI: 71.9--81.9%); or 4) phase II or III efficacy trials (74.2%; 95% CI: 69.0--79.4%). Studies that respondents would be less willing to participate in were: 1) stem cell transplants (54.0%; 95% CI: 48.1--59.9%) and 2) those involving latency-reversing agents (52.8%; 95% CI: 47.9--58.7%). Risks most likely to deter research participation included possible activation of proto-oncogenes (46.6%; 95% CI: 40.9--52.3%) and risks of developing resistance to ARVs (36.0%; 95% CI: 30.6--41.4%). The societal risk most likely to deter participation was transmitting HIV to others (26.3% 95% CI: 21.3--31.3%). Of the respondents, 26.7% (95% CI: 21.6--31.7%) would be very willing to interrupt treatment and 7.6% (95% CI: 4.6--10.6%) thought that a cure for HIV was presently available.

**Conclusions:** Data on willingness to participate are hypothetical and should not be used to predict enrollment rates; however, they can help anticipate practical issues affecting research implementation. The above results have implications for recruiting study participants and managing expectations around HIV cure science in the coming years. Given that some respondents thought a cure was currently available, heightened education efforts seem warranted.
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OP 9.0

Potential role for neutralizing antibodies in HIV-1 infection

J. Mascola

NIAID, Vaccine Research Center, Bethesda, MD, USA

Abstract not available at the time of printing
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OP 9.1

Targeting HIV reservoir by DART molecules that recruit T cells to HIV Env expressing cells: comparison of HIV arms derived from broadly reactive neutralizing or non-neutralizing anti-Env antibodies

J.L. Nordstrom^1^, D.D. Sloan^2^, C.Y. Kao Lam^1^, A. Irrinki^2^, L. Liu^1^, A. Tsai^2^, C.S. Pace^2^, J. Kaur^2^, J.P. Murry^2^, M. Balakrishnan^2^, P.A. Moore^1^, S. Johnson^1^, T. Cihlar^2^, S. Koenig^1^

^1^MacroGenics, 9640 Medical Center Drive, Rockville, MD, USA, ^2^Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA

**Background:** HIV reservoirs and production of viral antigens are not eliminated in HIV-infected individuals treated with combination antiretroviral therapy (cART) and novel therapeutic strategies are needed. Dual-Affinity Re-Targeting (DART) molecules exhibit a distinct mechanism of action via binding the viral envelope (Env) antigen on the surface of HIV-infected cells and simultaneously engaging CD3 on cytotoxic T lymphocytes (CTLs).

**Methods:** HIVxCD3 DART proteins were made in which HIV arms were derived from diverse broadly reactive Env-specific antibodies with (bnAbs) or without (non-nAbs) virus neutralizing activity. They were evaluated for antigen binding by ELISA, cell surface antigen binding by flow cytometry, CD8-dependent killing of HIV- infected Env-expressing target cells, and effect on virus propagation.

**Results:** HIVxCD3 DART proteins derived from two bnAbs (PGT121, PGT145) and two non-nAbs (A32, 7B2), but not from two other bnAbs (VRC01, 10E8), mediated potent CTL-dependent killing of quiescent primary CD4 T cells infected with diverse HIV isolates. Similar redirected CTL activity was also observed with DART molecules structurally modified for *in vivo* half-life extension. In an *ex vivo* model using cells isolated from HIV-infected individuals on suppressive cART, combinations of the most potent DART molecules reduced HIV expression both in quiescent and activated peripheral blood mononuclear cell cultures. Importantly, DART molecules did not induce cell-to-cell virus spread in resting or activated CD4 T cell cultures and ones with HIV arms derived from bnAbs retained virus neutralizing activity.

**Conclusion:** HIVxCD3 DART molecules potently and selectively mediate the killing of HIV-infected cells. Furthermore, they perturb resting and activated viral reservoirs in cells isolated from individuals on antiviral therapy. The data provide support for further pursuit of HIVxCD3 DART molecules as a promising therapeutic strategy for targeting HIV reservoirs.
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OP 9.2

CL572, a potent agonist of Toll-like receptor 2/7, as a novel latency-reversing agent

A. Macedo^1^, C.M. Assis^1^, C.L. Novis^1^, A. Spivak^2^, V. Planelles^1^, A. Bosque^1^

^1^Department of Pathology, University of Utah, Salt Lake City, UT, USA, ^2^Department of Medicine, University of Utah, Salt Lake City, UT, USA

**Background:** Successful therapies that target and reduce the latent HIV reservoir are a priority on the search of an HIV-1 cure. Previous findings in our laboratory demonstrated that Pam3CSK4 (a TLR1/2 ligand) is able to reactivate latent HIV-1 without global T-cell activation. So that, we decided to further study the potential application of TLR2 agonists as new latency -reversing agents (LRAs). CL572 is a synthetic multi-PRR agonist that has been recently shown to specifically activate human TLR2 and also TLR7. Our data indicate that CL572 can also efficiently reactivate latent HIV-1.

**Methods:** In order to perform our studies, we manipulated the tumoral cell line JLat 10.6 to increase TLR2 surface expression. We also tested the ability of CL572 to reactivate latent HIV-1 in a primary cell model of latency. Finally, we evaluated CD4+ T cells isolated from aviremic patients using the REVEAL assay (Rapid Ex Vivo Evaluation of Anti-Latency activity) that combines the ability to access viral reactivation, and to measure biomarkers of drug activity and toxicity in the same sample.

**Results:** We have observed that CL572 has activity in J-LAT cells expressing TLR2 and it retained activity at picomolar concentrations in this cell line. To confirm that CL572 is a more potent TLR-2 agonist that reactivates HIV-1 latency, we tested both Pam3CSK4 and CL572 in a primary cell model of latency. CL572 was less toxic than Pam3CSK4 in cultured T~CM.~ Additionally, CL572 is a more potent agonist of HIV-1 latency than Pam3CSK4 with activity in the lower nanomolar range. Finally, the REVEAL assay indicated that CL572 is able to trigger viral reactivation without T-cell activation and apoptosis in primary CD4 T cells.

**Conclusions:** These results indicate that CL572 can be utilized to trigger activation of latent proviruses in primary cells *in vitro.* Further investigations need to be done in order to verify if the reactivation triggered by CL572 alone is sufficient to sensitize reactivated T cells to the cytopathic effects of HIV-1 or whether CL572 has to be combined with other eradication strategies.
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OP 9.3

HIV conserved region vaccine in early cART-treated subjects (BCN01): impact on immunogenicity and the latent reservoir

S. Morón-López^1^, B. Mothe^1--3^, C. Manzardo^4^, A. Sanchez-Bernabeu^1^, P. Coll^1,2^, M.C. Puertas^1^, L. Dorrell^5^, J.M. Miró^2^, B. Clotet^1,2,3,6^, C. Brander^1,3,6,7^, J. Martinez-Picado^1,3,6,7^, T. Hanke^8^ for the BCN01 Study Group

^1^IrsiCaixa AIDS Research Institute-HIVACAT, Badalona, Spain, ^2^Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ^3^Universitat de Vic-Central de Catalunya (UVic-UCC), ^4^Hospital Clinic-IDIBAPS, Barcelona, Spain, ^5^John Radcliffe Hospital, Oxford, UK, ^6^Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, ^7^ICREA, Barcelona, Spain, ^8^Jenner Institute, University of Oxford, Oxford, UK

**Background:** Therapeutic T-cell vaccines targeting conserved regions of the HIV-1 proteome should enhance host immune control and contribute to reduce the latent viral reservoir.

**Methods:** BCN01 (NCT01712425) is a phase I, multicenter trial to evaluate the safety, immunogenicity and impact on the latent reservoir of ChAdV63 and MVA.HIVconsv vaccines in early-treated subjects (\<6 m from HIV-1, *n*=24) who initiated cART 1 week after diagnosis. Patients received ChAdV63.HIVconsv (5×10^10^ vp, im) and MVA.HIVconsv (2×10^8^ pfu, im), 8 or 24 weeks after (Short *vs.* Long regimen), and were followed for 6 months. Immunogenicity to HIVconsv insert and HIV-1 proteome was assessed by IFNγ ELISPOT. 24 controls were included to compare HIV reservoir decay during 1st year of early-cART. Proviral DNA was quantified in CD4+ T cells by droplet digital PCR. Single-copy assay was performed to investigate viral reactivation after vaccinations.

**Results:** Responses to conserved regions increased in all subjects after vaccinations. HIVconsv-specific T-cells peaked 1 or 4 weeks after MVA booster vaccination (median \[IQR\]: 938\[73--6,805\] SFC/million PBMC, *P*=0.0001 compared to pre-vaccination). No significant differences in peak or longevity were observed between regimens. Levels and decay of proviral DNA after cART were not associated with vaccine-induced immunogenicity nor differed from non-vaccinated individuals. Viral reactivation was not observed during vaccinations.

**Conclusions:** Vaccination with ChAdV63 and MVA.HIVconsv was a safe strategy to shift pre-existing immune response towards conserved regions of HIV-1 in a cohort of early-treated individuals, without inducing viral reactivation. Reservoir decay during first year of early-cART was not impacted by HIVconsv vaccinations. This is the first therapeutic vaccine trial that demonstrates a manipulation of CTL immunodominance pattern towards unmutated regions of HIV-1 and may facilitate clearance of the viral reservoir after HIV latency reactivation strategies.
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OP 9.4

Antiviral therapy by targeting nanoparticles to CD4+ cells for the delivery of SIV-specific RNA-guided Cas9 nucleases

L. Giavedoni^2^, L. Smith^1,2^, E. Carnes^3,4^, C. Lino^4^, V. Hodara^2^, K. Reimann^5^, L. Parodi^2^

^1^University of Texas Health Science Center, San Antonio, TX, USA, ^2^Texas Biomedical Research Institute, San Antonio, TX, USA, ^3^University of New Mexico, Albuquerque, NM, USA, ^4^Sandia National Laboratories, Albuquerque, NM, USA, ^5^University of Massachusetts Medical School, Boston, MA, USA

**Background:** Delivery of therapeutic materials to SIV-infected CD4+ T cells found deep within the body has proved a difficult task. Currently our group of collaborators is working on developing nanoparticles for the targeted delivery of vectors expressing RNA-guided nucleases. These materials will be loaded into mesoporous silica nanoparticles encased within supported lipid bilayers (protocells) conjugated with anti-CD4 antibodies to target delivery to SIV-infected cells *in vivo.*

**Methods:** We have developed SIV genome-specific RNA-guided nucleases targeting fifteen regions of the provirus. These guiding RNAs, which target highly conserved segments among the sequences of several SIVmac isolates, are designed to disrupt provirus via insertions and deletions in order to render virions non-infectious. *In vitro* assays in HEK293T cells co-transfected with a plasmid containing the SIVmac239 proviral genome and the individual RNA-guided nucleases were used to select the most effective constructs. Protocells internalization was tested by incorporating the fluorophore Dylite 633 inside particles coated with control antibody, or chimeric IgG~1~ or IgG~4~ anti-CD4 antibodies. Internalization was tested in uninfected or SIV-infected cell lines, or in rhesus white blood cells and PBMC.

**Results:** RNA-guided Cas9 nucleases targeting the LTR, the ribosome slip site (RSS) and the TAR regions showed a dramatic reduction in the levels of p27 antigen. Protocells conjugated with anti-CD4 IgG~4~ entered 97.2% of CD4+ T-cells, compared to 70.4% with α-CD4 IgG~1~. The same trend was seen when incubating the protocells with rhesus WBCs and CEM NK^r^ CCR5+ cells; SIV infection, which caused downregulation of CD4, did not affect the ability of α-CD4 IgG~4~ to facilitate internalization of protocells.

**Conclusions:** Preliminary results show that RNA-guided Cas9 nucleases can eliminate viral replication. Protocells conjugated with α-CD4 IgG~4~ show great promise for facilitating delivery of therapeutic materials into CD4+ T cells preferentially. These protocells will be loaded with vector encoded Cas9 to test whether the protocells can deliver effectively biomaterials to infected CD4+ T cell and reduce viral replication *in vivo*.
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OP 9.5

Potent CTL responses to conserved element of HIV to improve therapeutic DNA vaccine efficacy

B.K. Felber^1^, A. Valentin^1^, J.I. Mullins^2^, G.N. Pavlakis^1^

^1^National Cancer Institute, Frederick, MD, USA, ^2^University of Washington, Seattle, WA, USA

**Background:** We reported that therapeutic DNA vaccination in ART-treated macaques provides durable control of viremia after ART release. To improve efficacy, DNA vaccines were developed to overcome HIV sequence diversity and to address potential competition with decoy epitopes and to focus the immune responses to epitopes associated with virus control.

**Methods:** We engineered DNA-based immunogens consisting of conserved elements (CE) selected on the basis of stringent conservation, functional importance, broad HLA-coverage, and association with viral control. Gag CE DNAs were designed to maximize cross-clade coverage. Macaques were immunized in prime-boost regimens using CE DNA followed by DNA encoding Gag.

**Results:** All CE DNA-vaccinated macaques developed robust CE specific responses with a significant fraction of cytotoxic T cells. Interestingly, CE responses were significantly boosted in both magnitude and breadth upon vaccination with DNA expressing intact Gag, indicating altering of immune hierarchy by this vaccine regimen. We also found that vaccination-induced T cell responses rapidly disseminate into secondary lymphoid organs and effector mucosal sites.

**Conclusions:** Combination of CE and full-length immunogens provides a novel strategy to increase the magnitude and breadth of cellular immunity targeting subdominant conserved viral epitopes. These novel vaccines induce broad CTL responses to vulnerable sites of the virus, while avoiding variable regions that divert T cell responses towards less protective epitopes aiming to control potential escape mutants. This DNA vaccine regimen is being pursued to test whether targeting highly conserved regions by therapeutic vaccination could contribute to the cure of HIV infection. This vaccine will be combined with heterodimeric IL-15, a cytokine which we developed for clinical use and which has therapeutic potential by promoting growth, mobilization and activation of lymphocytes to further strengthen the immune response.
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OP 9.6

Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys

M. Luo^1,2^, D. Tang^1^, J. Pinto^3^, M. Nykoluk^1^, P. Lacap^1^, J. Tuff^1^, R. Capina^1^, C. Czarnecki^1^, J. Whitney^4^, M. Alonso^3^, T. Ball^2,5^, G. Kobinger^2,6^, P. Sandstrom^5^, F. Plummer^2,7^

^1^National Microbiology Laboratory, HIV Host Genetics/NHRL, Winnipeg, Canada, ^2^University of Manitoba, Medical Microbiology, Winnipeg, Canada, ^3^University of Santiago de Compostela, Santiago de Compostela, Spain, ^4^Harvard Medical School, Beth Israel Deconess Medical Center, Boston, USA, ^5^National Microbiology Laboratory, NHRL, Winnipeg, Canada, ^6^National Microbiology Laboratory, Special Pathogens, Winnipeg, Canada, ^7^National Microbiology Laboratory, Winnipeg, Canada

**Background:** Effective therapeutic vaccines used in combination of ARV to treat HIV infected patients can reduce drug induced toxicity, help to re-constitute immune system and achieve a functional cure. We conducted a pilot study to test the therapeutic effect of a novel HIV vaccine targeting the 12 protease cleavage sites in combination of ARV.

**Methods:** SIVmac251 infected rhesus monkeys were treated with a combination of FTC, PMPA and raltegravir for 49 days. Seven days after ARV initiation the monkeys in the treatment group received rVSVpcs (i.m.). Three additional therapeutic treatment with rVSVpcs (i.m.)/NANOpcs(i.m.), NANOpcs(i.m), and NANOpcs(i.m.) were carried out with 2-week intervals. ARV treatment was stopped after 49 days and viral load, CD4/CD8 counts, antibody and T cell response to PCS peptides and pooled Gag and Env peptide were analyzed.

**Results:** ARV treatment suppressed viral load of all macaques, but only the viral load of 6 out of 11 macaques was suppressed to non-detectable level during the treatment/ARV period. However, even with the short duration of ARV treatment and incomplete viral load suppression, the immune responses to PCS peptides were generated after 2--4 therapeutic treatments. The CD4 counts of PCS vaccine treated macaques were significantly improved after 35 days and 49 days of ARV treatment(*P*=0.027 and 0.044), whereas there is no significant improvement in CD4 counts of monkeys only received ARV treatment despite the viral load suppression.

**Conclusions:** Our study showed that new immune response to PCS peptides can be generated even with incomplete viral load suppression after a short period ARV treatment. The combination of PCS vaccine treatment and ARV generated new immune response to PCS peptides, improved CD4 counts of SIVmac251 infected monkeys and can be used to improve patient care to achieve a functional cure.
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OP 9.7

Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing

K. Khalili^1,2^, R. Kaminski^1,2^, Y. Chen^1,2^, T. Fischer^1,2^, E. Tedaldi^2,3^,A. Napoli^1,2^, Y. Zhang^1,2^, J. Karn^4^, W. Hu^1,2^

^1^Department of Neuroscience/Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA 19140, USA, ^2^Comprehensive NeuroAIDS Center, Temple University School of Medicine, Philadelphia, PA 19140, USA, ^3^Department of Medicine, Temple HIV Program, Temple University School of Medicine, Philadelphia, PA 19140, USA, ^4^Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA

The ability of HIV-1 to permanently integrate into the genomes of its target CD4+ T-cells presents a strong challenge for an HIV-1 cure, and none of the currently available approaches have achieved eradication of latent host-integrated HIV-1 DNA from patient T-cells. We used RNA-guided CRISPR/Cas9 DNA cleavage to precisely remove the entire HIV-1 genome spanning between 5′ and 3′ LTRs of integrated HIV-1 proviral DNA copies from latently infected human CD4+ T-cell lines.

Our CRISPR/Cas9 strategy completely ablated viral gene reactivation. Comprehensive assessment of whole-genome sequencing of HIV-1 eradicated cells with ultra-deep coverage of \>100x revealed many naturally-occurring insertion/deletion (InDel) mutations across the genome of control and HIV-1-eradicated cells, but none of these resulted from cleavage mediated by LTR-specific guide RNAs (gRNAs) aimed at host-integrated viral DNA. Furthermore, SURVEYOR assays ruled out any off-target effects that might compromise the integrity of the host genome, and we saw no side effects of HIV-1 genome removal, such as genotoxicity, dysregulation of the cell cycle, decreased cell viability or increased apoptosis. In addition, persistent co-expression of Cas9 and the specific targeting gRNAs in HIV-1-eradicated T-cells protected them against new infection by HIV-1. In primary CD4+ T-cell cultures, lentivirus-delivered CRISPR/Cas9 significantly diminished HIV-1 infection, evidenced by reduced viral copy numbers. Similarly, lentivirus-mediated delivery of Cas9 and HIV-1-targeting gRNAs *ex vivo* to cultured CD4+ T-cells obtained from HIV-1-infected patients undergoing antiretroviral therapy decreased viral replication by 68%--71%. Thus, gene editing using CRISPR/Cas9 may provide a new therapeutic path for eliminating HIV-1 DNA from CD4+ T-cells and potentially serve as a novel and effective platform toward curing AIDS.
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OP 10.0

The anti-inflammatory response and the HIV cure

R. Sekaly

Case Western Reserve University, Cleveland, USA

Abstract not available at the time of printing
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OP 10.1

Emergence of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy

K.R. Jerome^1,2,3^, D. Stone^1^, H.S. De Silva Feelixge^1^, P. Roychoudhury^1^, J.T. Schiffer^1,5^

^1^Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ^2^Department of Laboratory Medicine, University of Washington, Seattle, WA, USA, ^3^Department of Microbiology, University of Washington, Seattle, WA, USA, ^4^Department of Biochemistry, University of Washington, Seattle, WA, USA, ^5^Department of Medicine, University of Washington, Seattle, WA, USA

**Background:** Incurable chronic viral infections are a major cause of morbidity and mortality worldwide. One potential approach to cure persistent viral infections is via the use of targeted endonucleases. Nevertheless, a potential concern for endonuclease-based antiviral therapies is the emergence of treatment resistance. Here we demonstrate for the first time the emergence of an endonuclease-resistant infectious virus during endonuclease therapy.

**Methods:** We developed a series four of zinc finger nucleases (ZFNs) directed toward conserved sequences within the HIV *pol* gene, encoding protease, reverse transcriptase, or integrase. Activity of each ZFN against HIV sequences was confirmed in cell lines and primary human cells.

**Results:** While testing the activity of HIV *pol*-specific ZFNs alone or in combination with three prime repair exonuclease 2 (Trex2), we identified a treatment-resistant and infectious mutant virus (designated ZFN2 (+3)) that was derived from a ZFN-mediated disruption of reverse transcriptase (RT). Although gene disruption of HIV protease, RT and integrase could inhibit viral replication, a chance single amino acid insertion within the thumb domain of RT produced a virus that could actively replicate. The endonuclease-resistant virus could replicate in primary CD4+ T cells, but remained susceptible to treatment with antiretroviral RT inhibitors. When secondary ZFN-derived mutations were introduced into the mutant virus\'s RT or integrase domains, viral replication was abolished.

**Conclusions:** Our observations suggest that caution should be exercised using single endonuclease-based antiviral therapies. However, combination endonuclease therapies may prevent the emergence of resistance
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OP 10.2

The effects of combination of ingenol-B and ART to SIV251 infected rhesus monkeys

G. dos Santos Goncalves^1^, D. O'Connor^2^, S. O'Connor^2^, A. Tanuri^1^

^1^Universidade Federal do Rio de Janeiro, Brazil, ^2^University of Wisconsin-Madison, USA

Ingenol-B is a PKC agonist that has showed its potential to reactivate latent virus *in vitro* in experimental conditions. It was previously described that ingenol-B when administered to SIV chronically infected rhesus increased the viral load, proviral load and virus diversity. To evaluate the effect of ingenol-B combined with ART we have infected 6 rhesus with SIV for 6 weeks, followed by 24 weeks of ART. Four of the six monkeys received two cycles of 4 weeks of ingenol-B during the ART (tested group) and 2 monkeys only ART (control). After the monkeys were submitted to a washout phase with no drugs. Comparing the level of viral load before ART and the washout, the control group shows similar level with a decrease not greater than 3 fold. The tested group shows a pronounced decrease in the viral load of at least 5 fold, with one animal going from 10^6^ to 400 copies/mL, indicating a possible hole of ingenol-B on lowering the viral load. A deep sequencing analysis of the SIV env V1V2 region was done to access the viral diversity in each monkey. The control group had a higher diversity before ART then on the rebound during the washout. On the other hand, two of four monkeys on the tested group showed an increase in the viral diversity, one monkey showed similar diversity and one a slight decrease. Phylogenetic analysis of the viral subpopulations present on each monkey before ART and at the washout showed that the control monkeys present viral related subpopulations throughout the trial. While 3 out of 4 monkeys on the tested group show new subpopulations characterized by new branches on the trees. This may indicate that ingenol-B is responsible for maintaining the viral diversity on plasma by reaching viral reservoir and reactivating viral variants that would not produce virions. By doing this, ingenol-B could facilitate the action of the immune system finding and destroying former HIV latent cells, and contribute to decrease viral reservoir in patients.
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OP 10.3

Dendritic cell induced "kick" of latent HIV-1 *in vitro* during cART

R.B. Mailliard^1^, J. Kristoff^1^, D. Ratner, M. Ding, J.M. Zerbato^2^, N.D. Sluis-Cremer^2^, P. Gupta^1^, C.R. Rinaldo^1^

^1^Department of Infectious Diseases and Microbiology, University of Pittsburgh, PA, USA, ^2^Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

**Background:** Recently, increases in residual viremia were observed in cART-suppressed HIV infected individuals upon analytic treatment interruption after receiving a dendritic cell (DC)-based HIV vaccine, suggesting that DC may also play a role in HIV-1 latency reversal. Therefore, in this study we assessed the *in vitro* capacity of differentially programmed DC to drive latency reversal of replication-competent HIV-1 during cART.

**Methods:** Two models of HIV-1 latency reversal were tested: (1) Total resting CD4+ (rCD4) T cells from HIV-1 uninfected donors were treated with CCL19, infected with HIV-1~xxLAI~, exposed to low-dose IL-2 with efavirenz to establish latency, and subsequently stimulated with DC. (2) DC derived from HIV-1 infected individuals on cART (viral RNA \<20 copies/mL plasma) were co-cultured with autologous rCD4 T cells, in the absence or presence of efavirenz. The general role of antigen presentation was assessed using DC bound with either anti-CD3 (OKT-3) as an antigen surrogate, or the superantigen staphylococcal enterotoxin B (SEB). Three monocyte derived DC types were tested including immature DC (iDC), mature high IL-12p70 producing type-1 polarized DC (DC1), and mature IL-12p70 deficient DC (DC2). Cellular and culture supernatant viral RNA were quantified using qRT-PCR as well as a novel TZM-bl reporter cell based assay (TZA).

**Results:** All DC tested were found to induce replication competent virus from rCD4 T cells from HIV-1 infected participants on cART. However, DC1 consistently induced significantly greater levels of replication of HIV-1 RNA in rCD4 T cells than either iDC or DC2 in both models of HIV-1 latency reversal. Importantly, this DC-mediated effect was most pronounced in the presence of antigen.

**Conclusions:** While they are known to have a strong capacity to produce IL-12p70 and drive antigen specific CTL responses *in vitro*, this study demonstrates that DC1 are also superior to iDC and DC2 as a potential HIV-1 latency-reversal tool. Although the mechanisms of this effect have yet to be elucidated, the enhanced ability of DC1 to drive HIV-1 latency reversal was antigen dependent. Information resulting from these studies will be used towards the design of novel DC1-based vaccine strategies to facilitate the "kick" as well as the "kill" of the HIV-1 reservoir.
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OP 10.4

Peripheral blood lymphocytes from patients with chronic myeloid leukemia on treatment with dasatinib are resistant to HIV-1 infection

M. Coiras^1^, M. Bermejo^1^, J. García-Pérez^1^, J. Ambrosioni^2^, J.M. Miró^2^, M. Plana^3^, J. Alcamí^1^

^1^AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain, ^2^Infectious Diseases Service, AIDS Research Group, Institut d\'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain, ^3^Retrovirology and Viral Immunopathology Laboratory, AIDS Research Group, Institut d\'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain

**Background:** Massive activation of infected CD4 cells during acute HIV-1 infection leads to neutralization of the antiviral effect of SAMHD1 through its phosphorylation. Dasatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML), has been described to control HIV-1 replication through its negative effect on viral entry. We demonstrated that dasatinib actually interferes with SAMHD1 phosphorylation, preserving its antiviral activity against HIV-1.

**Materials:** PBMCs from healthy donors to determine the effect of dasatinib on SAMHD1 phosphorylation and HIV-1 fusion step. PBMCs from CML patients on treatment with dasatinib to analyze SAMHD1 phosphorylation and susceptibility to HIV-1 infection *ex vivo*.

**Results:** Dasatinib prevented SAMHD1 phosphorylation, preserving its antiviral activity and impairing HIV-1 retrotranscription and proviral integration. This was the major mechanism of action because Vpx, which degrades SAMHD1, impeded the inhibitory effect of dasatinib on HIV-1 replication. Fusion of BlaM-Vpr-containing HIV-1 viruses with activated PBMCs in the presence of dasatinib showed that dasatinib was not acting at fusion level. PBMCs from five CML patients on chronic treatment with dasatinib for more than two years showed reduced phosphorylation of SAMHD1 in response to T-cell activation *ex vivo*. These cells were resistant to HIV-1 infection *ex vivo*, showing very low proviral integration.

**Conclusions:** Dasatinib is the first compound currently used in clinic that has been described to preserve the function of the innate antiviral factor SAMHD1. The use of dasatinib with antiretroviral therapy during primary HIV-1 infection could control massive activation of CD4 cells, making them refractory to infection by interfering mostly with retrotranscription. This would reduce the reservoir size and preserve HIV-specific immune responses, creating a more favorable immunologic environment for future interventional studies aiming at HIV-1 eradication and cure.
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OP 10.5

Restricted HIV-1 diversity and clonal expansion following cytoreductive chemotherapy

T.J. Henrich^1,2^, E.P. Scully^3^, K.S. Hobbs^1,2^, E. Hanhauser^1,2^, L.E. Hogan^1,2^, C.D. Palmer^3^, Y.P. Robles^1^, K.S. Leadabrand^2^, A.S. LaCasce^4^, D.R. Kuritzkes^1^

^1^Brigham and Women\'s Hospital, Boston, MA, USA, ^2^University of California San Francisco, San Francisco, CA, USA, ^3^Ragon Institute of MGH, MIT and Harvard, USA, ^4^Dana-Farber Cancer Center, Boston, MA, USA

**Background:** Cytoreductive chemotherapy does not lead to consistent changes in HIV-1 DNA or RNA. However, reductions in CD4 T cells during chemotherapy suggest that reservoirs decrease. Constriction and subsequent oligoclonal expansion of HIV diversity is a better measure of the reservoir response to HIV eradication strategies. We examined HIV sequence evolution in the context of immune correlates, and quantified reservoirs in cells responding to non-HIV stimuli.

**Methods:** Longitudinal, single-genome HIV envelope sequencing was performed in 10 individuals on ART receiving cancer chemotherapy. Changes in T cell subsets, activation/proliferation and HIV-specific immune responses were measured. HIV was quantified from CD4 T cells sorted on intracellular IL2 and/or INFγ staining after stimulation with αCD3/αCD28 or combined EBV/CMV lysates.

**Results:** Although CD4 T cell counts decreased by up to 75%, CD4 T cell HIV DNA did not change and RNA increased following completion of chemotherapy (*P*=0.203 and *P*=0.037). Despite temporary reductions in cell counts, no changes in the percentage of naive, central or effector memory CD4 and CD8 T cell subsets were observed. Markers of activation/proliferation decreased or remained stable in all populations, but HIV-specific T cell responses either increased or developed novel signatures following chemotherapy. Clonal expansion of HIV-1 envelope sequences following completion of chemotherapy was observed in three of six patients for whom data was obtained. CD4 T cells that responded to EBV/CMV lysates had higher HIV DNA levels compared to those that did not respond or responded to αCD3/αCD28 stimulation.

**Conclusions:** Despite the lack of changes in peripheral blood HIV DNA, our results suggest that cytoreductive therapy reduces HIV reservoirs in some patients manifesting as a constriction of HIV sequence diversity. Our data also suggest that response to non-HIV antigens can lead to oligoconal expansion of the DNA reservoir.
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OP 10.6

Dual-affinity re-targeting (DART) proteins overcome viral diversity to deplete the latent HIV-1 reservoir

J.M. Sung, J. Pickeral, M. Bednar, L. Liu, S.A. Stanfield-Oakley, J. Pollara, C. LaBranche, M.A. Moody, M. Bonsignori, C.Y. Kao Lam, S. Johnson, C. Garrido, N. Archin, J. Kuruc, M. Cohen, K. Soderberg, H.X. Liao, D. Montefiori, R. Swanstrom, S. Koenig, J. Nordstrom, B.F. Haynes, G. Ferrari, D. Margolis

University of North Carolina, Chapel Hill, NC, USA

**Background:** Dual-Affinity Re-Targeting (DART) proteins are bispecific, antibody derived molecules consisting of an HIV binding arm based on broadly binding antibodies targeting highly conserved regions of Env, coupled to a binding arm for CD3 T-cells. We reported that DARTs clear HIV-1 infected cells, including rare latently infected cells following exposure to vorinostat. We now report initial data on viral sequences in the single patient in whom the kinetics of viral clearance by DARTs was delayed.

**Methods:** A viral clearance assay to assess DART activity against targets infected with autologous reservoir virus. A latency clearance assay measured the ability of DARTs to clear patient resting CD4 T cells induced to express viral antigens either by stimulation with PHA, or with clinically relevant doses of vorinostat.

**Results:** Addition of DARTs to a viral clearance assay led to a significantly greater log fold reduction in autologous reservoir virus compared to co-culture with CD8 T cells alone (0.79 *vs.* 0.02, respectively, *P*\<0.05). Addition of DARTs to a latency clearance assay with PHA-stimulated latently infected cells reduced viral recovery in all six out of six subjects. Viral recovery from vorinostat exposed resting CD4 T cells was also reduced in three out of four subjects. Importantly sequencing of outgrowth virus from cells of the one subject without an initial response to DARTs did not detect any mutations to the binding residues for DARTs, and prolonging the co-culture period led to complete ablation of viral recovery.

**Conclusion:** Viral clearance assays and sequencing demonstrate that DARTs are capable of redirecting T cells against cells infected with autologous reservoir virus and resting CD4 T cells emerging from latency. The kinetics of viral clearance require further study, but there is thus far no evidence of viral escape from DARTs. In combination with latency-reversing agents, DARTs may be potent tools to deplete the latent HIV-1 reservoir.
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OP 10.7

Human galectin-9 is a potent mediator of HIV transcription and reactivation

M. Abdel-Mohsen^1,2^, L. Chavez^1^, G.M. Chew^3^, X. Deng^1^, A. Danesh^1,2^, S. Keating^1^, R. Hoh^2^, S.G. Deeks^2^, L.C. Ndhlovu^3^, S.K. Pillai^1,2^

^1^Blood Systems Research Institute, San Francisco, CA, USA, ^2^University of California, San Francisco, USA, ^3^University of Hawaii, Hawaii Center for AIDS, John A. Burns School of Medicine, Honolulu, HI, USA

**Background:** Based on our recent finding that the host factor p21 regulates HIV transcription during antiretroviral therapy (ART), and published data demonstrating that the glycan-binding protein galectin-9 (Gal-9) regulates p21, we hypothesized that Gal-9 modulates HIV transcription.

**Methods:** Plasma Gal-9 levels were examined in relation to measures of the latent HIV reservoir in 72 HIV-infected ART-suppressed individuals. The ability of recombinant Gal-9 (rGal-9) to reactivate latent HIV was evaluated *in vitro* and *ex vivo*. Cell-surface deglycosylation was used to explore the requirement of glycans in viral reactivation by rGal-9. Effects of rGal-9 on the host transcriptome were evaluated using RNA-seq.

**Results:** Endogenous levels of Gal-9 were associated with HIV transcription (*P*\<0.02) *in vivo* during ART. rGal-9 reactivated virus in J-Lat cells (15.1%) more potently than anti-CD3/CD28 stimulation (4.8%, *P*\<0.0001). In CD4+ T cells from 13 HIV-infected ART-suppressed individuals, rGal-9 induced a mean 7.3-fold increase in intracellular HIV RNA levels (*P*=0.002). Induction was significantly higher than vorinostat (*P*=0.02, 3.2 fold). Cell surface N-linked oligosaccharides and O-linked hexasaccharides were essential for rGal-9-induced HIV reactivation, mediated by key transcription initiation, and chromatin remodeling factors (FDR\<0.05). rGal-9 induced expression of APOBEC3G up to 29-fold *in vitro* and *ex vivo* (FDR\<0.006), resulting in 6.7-fold reduction in infectivity of progeny virus.

**Conclusions:** rGal-9 potently reactivates latent HIV and induces APOBEC3G expression *in vitro* and *ex vivo*. rGal-9-induced virus will likely be rendered replication-incompetent as a result of APOBEC3G induction in the producer cell, ensuring that the reservoir will not be replenished when latency is reversed, even in the setting of suboptimal ART suppression. Our data suggest that galectin-9 and the glycosylation machinery should be explored as a foundation for novel HIV cure strategies.
